

1 **Title:** Paving the way for human vaccination against Rift Valley fever virus:

2 A systematic literature review of RVFV epidemiology from 1999 to 2021

3

4 **Short Title:** Review of RVFV epidemiology for a human vaccination trial

5 **Authors:** Keli N. Gerken<sup>1</sup>, A. Desirée LaBeaud<sup>1</sup>, Henshaw Mandi<sup>2</sup>, Maïna L’Azou

6 Jackson<sup>3</sup>, J. Gabrielle Breugelmans<sup>2</sup>, Charles H. King<sup>4\*</sup>

7 <sup>1</sup>Division of Pediatric Infectious Diseases, Department of Pediatrics, Stanford University

8 School of Medicine, Stanford, California, USA

9 <sup>2</sup>Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway

10 <sup>3</sup>Coalition for Epidemic Preparedness Innovations (CEPI), London, UK

11 <sup>4</sup>Center for Global Health and Diseases, Department of Pathology, Case Western

12 Reserve University School of Medicine, Cleveland, Ohio, USA

13

14 Word count, abstract: 332

15 Word count, manuscript: 11402

16 Tables: 3 (13 supplementary)

17 Figures: 10 (3 supplementary)

18

19 \*Corresponding author:

20 Email: [charlesking48@gmail.com](mailto:charlesking48@gmail.com) (CHK)

21

22

## 23 **Abstract**

24 **Background:** Rift Valley fever virus (RVFV) is a lethal threat to humans and  
25 livestock in many parts of Africa, Arabia, and the Indian Ocean. This systematic review's  
26 objective was to consolidate understanding of RVFV epidemiology during 1999-2021  
27 and highlight knowledge gaps relevant to plans for human vaccine trials.

28 **Methodology/Principal Findings:** The review is registered with PROSPERO  
29 (CRD42020221622). Reports of RVFV infection or exposure among humans, animals,  
30 and/or vectors in Africa, the Arabian Peninsula, and the Indian Ocean during the period  
31 January 1999 to June 2021 were eligible for inclusion. Online databases were searched  
32 for publications, and supplemental materials were recovered from official reports and  
33 research colleagues. Exposures were classified into five groups: 1) acute human RVF  
34 cases, 2) acute animal cases, 3) human RVFV sero-surveys, 4) animal sero-surveys,  
35 and 5) insect infections. Human risk factors, circulating RVFV lineages, and surveillance  
36 methods were also tabulated. In meta-analysis of risks, summary odds ratios were  
37 computed using random-effects modeling. 1104 unique human or animal RVFV  
38 transmission events were reported in 39 countries during 1999-2021. Outbreaks among  
39 humans or animals occurred at rates of 5.8/year and 12.4/year, respectively, with  
40 Mauritania, Madagascar, Kenya, South Africa, and Sudan having the most human  
41 outbreak years. Men had greater odds of RVFV infection than women, and animal  
42 contact, butchering, milking, and handling aborted material were significantly associated  
43 with greater odds of exposure. Animal risk was linked to location, proximity to water,  
44 and exposure to other herds or wildlife. RVFV was detected in a variety of mosquito  
45 vectors during interepidemic periods, confirming ongoing transmission.

46           **Conclusions/Significance:** With broad variability in surveillance, case finding,  
47 survey design, and RVFV case confirmation, combined with uncertainty about  
48 populations-at-risk, there were inconsistent results from location to location. However, it  
49 was evident that RVFV transmission is expanding its range and frequency. Gaps  
50 assessment indicated the need to harmonize human and animal surveillance and  
51 improve diagnostics and genotyping. Given the frequency of RVFV outbreaks, human  
52 vaccination has strong potential to mitigate the impact of this now widely endemic  
53 disease.

54

## 55 **Author Summary**

56           Rift Valley fever virus (RVFV) is a globally important mosquito-transmitted  
57 zoonosis that is also directly transmissible via aerosolization of body fluids from infected  
58 animals. RVFV outbreaks cause mass mortality of young livestock and pregnancy  
59 losses in both humans and animals. Severe human cases also result in hemorrhagic  
60 fever, encephalitis, and death. Loss of livestock additionally threatens the livelihood of  
61 people who depend on animals for income and food. In endemic areas, initiation of  
62 RVFV outbreaks is connected to weather events that cause excess rainfall, leading to  
63 flooding and subsequent mosquito blooms. However, the natural cycle of RVFV  
64 transmission is complex, requiring congregation of susceptible mammalian hosts and  
65 mosquito vectors in suitable environments. Several human vaccine candidates are in  
66 different stages of development, but none are yet licensed for use in human  
67 populations. In this systematic review, we assessed the 1999-2021 frequency and  
68 distribution of RVFV outbreaks among humans, animals, and vectors to identify

69 potential locations and population targets for a human RVFV vaccine efficacy trial. It  
70 focuses on current understanding of RVFV epidemiology and the identification of gaps  
71 that pose critical barriers to controlling expansion of RVFV and implementing new  
72 protective measures including human vaccination.

73

74

## 75 **Introduction**

76 Rift Valley fever virus (RVFV) remains an important emerging arboviral pathogen  
77 due to its recent geographic spread and its combined disease and financial impacts on  
78 vulnerable human populations [1]. Specifically, RVFV is listed as a priority pathogen by  
79 the World Health Organization (WHO), the Food and Agriculture Organization of the  
80 United Nations (FAO), and the U.S. Centers for Disease Control and Prevention (CDC)  
81 because of its ability to cause life-threatening hemorrhagic fever and encephalitis in  
82 humans [2, 3], its epidemic potential to cause severe harm to livestock [4, 5], and its  
83 potential for non-vector aerosol spread during epizootics and epidemics [6, 7]. The RVF  
84 virus is a member of the *Phlebovirus* genus, with three main lineages, with East African,  
85 West African, and Southern African groupings.

86 RVFV was first identified in 1931 during an investigation into an epidemic of  
87 fatalities among sheep on a farm in the Rift Valley Province of Kenya [8]. Since that  
88 time, its spatial range has continued to expand from East Africa into southern Africa,  
89 West Africa, and North Africa, and more recently outside Africa to the Arabian Peninsula  
90 [6, 7, 9]. RVFV can infect a wide range of mammalian hosts [10] and can be carried by  
91 many insect vectors. Floodwater *Aedes spp.* are important in maintenance during

92 interepidemic periods, whereas other Diptera serve as secondary vectors during  
93 outbreaks in sub-tropical and temperate regions of the world [11-15]. RVFV results in  
94 lower case fatality rates (CFR) compared to other hemorrhagic fever viruses [4], but its  
95 outbreaks have profound compounding effects on human subsistence (from loss of  
96 livestock) and on national economies, related to livestock export bans [16-19].

97         The critical environmental reservoir of RVFV is presently unknown. Humans  
98 become infected either through the bite of an infected vector or through exposure to  
99 infectious animal tissues or bodily fluids such as abortus, birthing fluids, meat, milk, or  
100 blood aerosolized during slaughtering. Other than *in utero* transmission, there is no  
101 evidence for human-human transmission of RVFV [4]. Those infected either remain  
102 minimally symptomatic or develop a mild form of the disease Rift Valley fever (RVF)  
103 (96% of patients), which is characterized by a febrile syndrome with sudden onset of flu-  
104 like fever, muscle pain, joint pain, and headache [4]. Some patients develop neck  
105 stiffness, sensitivity to light, loss of appetite and vomiting and therefore RVF can be  
106 mistaken for meningitis [20]. While most human cases are relatively mild, a small  
107 percentage of patients will develop a much more severe form of the disease [21]. This  
108 usually appears as one (or more) of three distinct syndromes: ocular (eye) disease  
109 (0.5–2% of patients), meningoencephalitis (fewer than 1% of patients) or hemorrhagic  
110 fever (fewer than 1% of patients) [4].

111         Equally important is the lethal threat to peoples' livestock. RVFV spread into  
112 naïve ecosystems is driven by infected animal movement and potentially via infected  
113 vectors [22], and can result in death of between 70-90% of young ruminants with sheep  
114 the most affected, and loss of pregnancy in nearly 100% of pregnant animals [23].

115 Outbreaks in humans and in animals do not occur at random. Instead they are  
116 strongly linked to excess rainfall and to local flooding events [24] and the consequent  
117 rise in mosquito abundance [25-32]. In addition, there is mounting evidence that  
118 suggests that there is continuing low-level RVFV transmission to humans and to  
119 animals between recognized epidemic periods [33-49]. Undetected infections,  
120 particularly in livestock, provide an important reservoir for recurrent outbreaks, leading  
121 to a continuing threat of disease in economically marginal communities and risk of  
122 further geographical expansion.

123 The specific objective of this study was to consolidate the understanding of  
124 recent RVF epidemiology over the recent 1999-2021 period. We sought to catalogue  
125 the variability of national/regional incidence and prevalence, human risk factors and  
126 populations at risk, the geospatial distribution of RVF serotypes/lineages, and the  
127 present day national and regional human and animal RVF/viral hemorrhagic fever  
128 surveillance systems. The systematic review also highlighted current knowledge gaps in  
129 RVFV epidemiology to establish the major challenges remaining for current efforts in  
130 development and testing of human vaccine.

131

## 132 **Methods**

133 To meet our study goals, we performed a systematic review of the available  
134 published literature as well as governmental monitoring and media reports of RVF  
135 activity during the period 1999-2021. The study results are reported according to the  
136 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA  
137 2020) guidelines [50]. See S1 Table for details.

138           **Inclusion/exclusion criteria.** Studies included in the review were those that  
139 contained reports of human, animal, and/or vector RVFV infection or exposure among  
140 individuals (of any age) in countries across Africa, the Arabian Peninsula, and the Indian  
141 Ocean where RVFV transmission was detected during the period January 1<sup>st</sup> 1999 to  
142 June 1<sup>st</sup> 2021, including historical, observational, and prospective studies. Serosurveys  
143 from outside this target area (Spain [51, 52], Poland [53], Korea [54], and Jordan [55])  
144 were also catalogued, although not formally included in our analysis. Reports containing  
145 primary human seroprevalence or incidence data, reported RVF outbreaks or cases,  
146 details of RVF transmission, RVFV lineage distribution, and/or risk factors were  
147 included. Reports of infections among regional livestock and wildlife during the same  
148 period were also included.

149           The primary objective was to obtain population-based survey data. However,  
150 georeferenced location-specific case reports were also included in spatiotemporal  
151 analysis. There was no restriction according to the language of publication.

152           Excluded studies were those that reported laboratory-based studies or  
153 intervention trials among experimental animals in controlled settings. Reports, reviews,  
154 or opinion articles without primary data were also excluded.

155           **Information sources and search strategy.** To maximize detection of eligible RVFV  
156 transmission studies, we searched the online databases PubMed, Web of Science,  
157 African Journals Online, The Cumulative Index to Nursing and Allied Health Literature  
158 (CINAHL), The Scientific Electronic Library Online (SciELO), Elsevier, ResearchGate,  
159 and the Program for Monitoring Emerging Diseases (ProMED) listserv site. Animal  
160 outbreak data recorded by the World Organization for Animal Health (OIE) was

161 recovered from their databases, the 2005-2021 WAHIS (<https://wahis.oie.int/#/home>),  
162 and the older Handistatus II database (<https://web.oie.int/hs2>). Other sources of papers  
163 and reports that were also retrieved included: i) polling colleagues involved in RVF  
164 research or control for any non-indexed 'grey literature', ii) using Google Scholar  
165 referrals for 'similar papers', iii) scanning of literature found in personal archives, and iv)  
166 obtaining non-indexed citations found among the reference lists of the papers reviewed  
167 in our study. Unpublished data from a recent survey study in Nigeria was also included  
168 (Bonto Faburay and colleagues, personal communication). Details of the information  
169 sources and search strategy used are available in S1 Text.

170 **Selection process.** Review of titles and abstracts was performed by two trained  
171 reviewers who independently searched for data content meeting study requirements.  
172 The studies found potentially suitable for inclusion after title-abstract review were then  
173 obtained for full-text review from online or library sources. Where a single report  
174 contained data on multiple individual community surveys, each of these surveys was  
175 separately abstracted and given a unique ID number for inclusion in sub-group  
176 comparison analyses. Studies with insufficient details of the incidence or prevalence of  
177 RVFV infection were not included, and cases of duplicate publication or extended  
178 analysis of previously published data were removed from the list of selected references  
179 for this review. Full listings of included and excluded references are provided as  
180 Supporting Information files S2 and S3 Tables.

181 **Data collection process.** Included papers were abstracted by two independent  
182 reviewers, and their relevant features entered into a purpose-built database created with  
183 Google Forms. The entries were then stored in a shared master spreadsheet in Google



184 Sheets. The included papers and data registry downloads were archived in electronic  
185 text (pdf) or spreadsheet formats at the Department of Pediatrics, Stanford University  
186 School of Medicine, and at the Center for Global Health and Diseases, Case Western  
187 Reserve University.

188 **Data items.** For the human and animal RVFV exposures or clinical cases reported,  
189 information was entered into the database based on UN geographic region  
190 (<https://unstats.un.org/unsd/methodology/m49>), country, and the sub-national  
191 administrative location details that were reported. Islands in the Indian Ocean, normally  
192 classified as 'Eastern Africa' by the UN, were grouped separately for our analyses. The  
193 beginning and ending month and year of the reported RVF activity or exposure study  
194 were recorded, as well as information about whether the event was a recurrence of  
195 transmission in a previously affected area, whether there had been flooding before the  
196 event, and whether the period involved an El Nino-Southern Oscillation (ENSO) event.  
197 When outbreaks spanned more than one calendar year, the year of onset was used to  
198 classify the event. Study design and the eligible study population were recorded for  
199 each report and whether the report involved human cases, domestic or wildlife animals,  
200 or insect vectors, and the number of affected individuals by species. Where available,  
201 age and gender distributions were captured for both animal and human studies, along  
202 with any potential risk factors that were studied, and which were found to be significant  
203 by that study. Factors evaluated for human exposure risk were age and age class,  
204 gender, occupation, socio-economic status, and participation in the animal care  
205 activities of feeding, herding, sheltering, or milking livestock, as well as assisting birth,  
206 butchering, or skinning, and disposal of aborted material, or consumption of raw milk.

207 Factors evaluated for animal RVFV exposure were age and age class, sex, breed, body  
208 condition, herd size, grazing strategy, and environmental conditions including proximity  
209 to water, local vegetation, rainfall, and mosquito control measures. Our data extraction  
210 tool was designed to capture factors related to the area the animal was raised (water  
211 sources nearby, mosquito exposures, rainfall, vegetation), herd factors (grazing  
212 strategy, mosquito control measures, herd size) and individual risk factors such as body  
213 condition and breed. In some animal studies, the age of the animal (by dental  
214 examination) and sex could be objectively assessed at the time of sampling. We  
215 grouped common animal exposures and determined how many studies had assessed  
216 for the risk factor and how many individual studies found statistically significant results  
217 by bivariate or multivariate analyses. Not all studies separated the species of animals  
218 involved within each exposure, and these have been reported as “not subdivided by  
219 species.” Information was recorded on the diagnostic tests used to identify acute cases  
220 or exposures, and on each study’s criteria used to identify suspected and confirmed  
221 animal or human cases of RVF. Available information regarding local RVF surveillance  
222 methods was noted, as well as any information about the RVFV lineage involved in the  
223 reported cases. Where individual outbreaks were reported in more than one publication  
224 or governmental bulletin, case numbers and mortality for that outbreak were taken from  
225 the latest reports.

226 **Study risk of bias assessment.** We used an abridged version of the Liverpool Quality  
227 Appraisal Tool (LQAT) [56, 57] to assess study quality and risk of bias of included  
228 studies because of the tool’s flexibility in accommodating different study designs and in  
229 creating potential bias assessments specific to our diverse set of studies. Scoring

230 involved assessment of possible subject selection bias, response bias, follow up bias,  
231 bias in risk factor assessment, bias in outcome assessment, or possible bias in  
232 reporting the outcome. Scoring also included whether the study's analysis involved  
233 adjustment for potential confounders. The LQAT score, combined with recorded  
234 information about study design and power, were used to classify reports as weak (score  
235 1-5), moderate (score 6-8), or strong evidence (score 9 or 10) regarding local risk for  
236 disease or exposures. Each study was assessed independently by two reviewers with  
237 discrepancies resolved in consultation with a third reader.

238 **Effect measures.** We enumerated the cumulative number of outbreaks reported within  
239 national and sub-national borders over time, and the observed incidence or period  
240 prevalence by location. However, because of significant heterogeneity created by  
241 reporting bias, relative risk comparisons among the multiple locations were considered  
242 unreliable. Continent-wide RVF risk assessment for Africa, based on climate, weather,  
243 population, and landscape factors has been recently well studied [58-63] and so was  
244 not repeated here. We have, however, updated prior meta-analysis assessment [64] of  
245 individual human risk factors to provide evidence regarding specific sub-groups who  
246 might serve as suitable high-risk subjects for a human vaccine trial. Because the  
247 chances of infection were based on post hoc determination of exposures, summary  
248 odds ratios, derived by random effects statistical modeling, were used to determine the  
249 strength of these associations in the meta-analysis.

250 **Synthesis methods.** Outbreaks and exposures were classified into five groups: 1)  
251 acute human RVF cases, 2) acute animal cases, 3) human RVFV exposure data (based  
252 on sero-surveys), 4) animal exposure data, and 5) insect infection data. These were

253 tabulated over time and space using frequency measures and geo-located, when  
254 necessary, using Google Earth Pro software (available at  
255 <https://www.google.com/earth/versions/>). The two decades of inclusion (1999-2010 and  
256 2001-2021) were assessed jointly and then separately to determine the evolution of  
257 disease, changes in detection of disease through improved diagnostics, and the effects  
258 of more robust surveillance. Regional maps at the national and sub-national level were  
259 then prepared using QGIS software (<https://www.qgis.org/en/site/>) using base maps  
260 supplied by the Database of Global Administrative Areas (GADM) (version 3.4, (April  
261 2018, [www.gadm.org](http://www.gadm.org), licensed for non-commercial purposes). Surveillance systems in  
262 animals, humans, and vectors were categorized either as early warning systems,  
263 detection in hospital-based surveys, use of sentinel herds for surveillance, or farmer  
264 reported syndromic surveillance. For meta-analysis of individual human level risk  
265 factors, results from those included studies with relevant human exposure data were  
266 entered into Comprehensive Meta-Analysis software, v.3 (CMA, Biostat, Englewood,  
267 NJ) for calculation of pooled summary estimates of exposure effects, along with their  
268 confidence intervals. Heterogeneity levels were scored using Higgins's and Thompson's  
269  $I^2$  statistic [65]. Summary estimates of intervention effects were computed using Der  
270 Simonian and Laird random-effects modeling [66] implemented by the CMA software.  
271 Summary data were presented visually by Forest plots showing the respective odds  
272 ratio and 95% confidence interval ( $CI_{95\%}$ ) for the pooled analysis. Assessment for  
273 potential publication bias was carried out by visual inspection of funnel plots, and  
274 statistically by calculating the Egger test. To explore heterogeneity and factors that  
275 could potentially modify the summary estimates of effect, we performed subgroup


276 analyses stratified by study risk of bias, and by year of publication. For the sensitivity  
277 analysis, each meta-analysis was retested with the exclusion of one study at a time to  
278 assess the possibility of a disproportionate impact of any individual study on summary  
279 estimates.

280

## 281 **Results**

### 282 **Studies and RVFV reports selected for inclusion**

283 Initial screening of online publication databases yielded 7097 listings for RVF or RVFV  
284 during the period January 1999-June 2021 for our initial review (Fig 1). These were  
285 supplemented by 771 georeferenced outbreak case reports obtained from OIE  
286 databases World Animal Health Information System (WAHIS,  
287 <https://wahis.oie.int/#/home>) for events after 2004, and from OIE Handistatus II  
288 (<https://web.oie.int/hs2/report.asp?lang=en>) for earlier 1999-2003 events. Other  
289 sources, including private archives, governmental reports, ProMed listings, listings from  
290 previous systematic reviews [64, 67], and non-indexed citations (found in Google  
291 Scholar and in bibliographies of papers under review), provided an additional 667  
292 reports for consideration for possible inclusion. After removal of duplicates, 1976 unique  
293 articles or reports were selected for full text review. After the full text review was  
294 performed, 285 events reported in 281 publications, plus the 771 events identified in  
295 OIE databases and 48 from grey literature, identified a total of 1104 unique human or  
296 animal RVFV transmission events for inclusion in the analysis.



297

298 **Fig 1. PRISMA systematic review flow diagram of data collection and evaluation**

299 Online searches for publications and data registers (left side flow) were supplemented  
300 by governmental outbreak reports, non-indexed citations found in local archives, and  
301 citations found within the reference lists of the papers that were reviewed (right side  
302 flow). Data from one unpublished study were also included for evaluation.  
303

304 **Report characteristics**


305 Of the 285 included reports selected from the published literature, 91% were in peer-  
306 reviewed journals, 7% were in governmental reports, and 2% were in abstracts or  
307 published correspondence. Following the regional designations of the United Nations,  
308 43% of these papers reported RVF activity in East Africa, 13% in West Africa, 13% in  
309 the Arabian Peninsula, 10% in North Africa, and 10% in Southern Africa. The countries  
310 of Kenya (n= 42 reports), Saudi Arabia (n= 32), Tanzania (n = 24), South Africa (n= 22),  
311 Madagascar (n= 14), Sudan (n= 13), Mauritania (n= 11), and Mozambique (n= 11) were  
312 the most frequent subjects of RVF outbreak reports and surveys. Thirty percent of  
313 reports documented acute outbreaks (epidemics/epizootics), 61% were exposure  
314 studies performed during interepidemic periods, and 7% were post-epidemic survey

315 studies. One hundred sixty-five (58%) were cross-sectional surveys of humans or  
316 animals, 60 (21%) were acute case series, 35 (12%) involved prospective cohorts, and  
317 4 (1%) were case-control studies. Forty-two (15%) reported on vector testing in affected  
318 areas. Among published studies, 195 (68%) were non-randomized, 79 (28%) involved  
319 some form of random sampling, and 11 (4%) did not clearly indicate how sampling was  
320 done. In terms of study quality, the median LQAT score for published studies (where  
321 higher scores indicated higher quality studies) was 6 (range = 2-11, IQR 5-7), meaning  
322 the majority of studies had moderate-to-high risk of bias in assessing risk by location or  
323 by sub-population. Details of all included studies, including individual risk-of-bias scores  
324 are provided in S2 Table.

### 325 **Where RVFV transmission or RVF epidemics/epizootics occurred, 1999-2021**

326 Overall, 39 countries had evidence of RVFV circulation in humans, animals, or  
327 vectors during the 1999-2021 period, based on detection of probable or confirmed acute  
328 cases, positive PCR testing, or serosurvey results (Fig 2 and S4 Table). Eighty-three  
329 reports documented 124 locations in 19 countries that had 4,353 probable or confirmed  
330 acute human RVF cases and 755 deaths (Fig 3), whereas 107 reports documented  
331 acute RVF animal events (470 OIE confirmed cases) in 31 countries between 1999 and  
332 2021 (Fig 4). The median year of reported events was 2010. Outbreaks of clinical  
333 disease among humans or animals occurred at average rates of 5.8/year and 12.4/year,  
334 respectively, with Mauritania, Madagascar, Kenya, South Africa, and Sudan having the  
335 most human outbreak years. When month of onset was given for acute outbreaks  
336 reports (epizootics or epidemics), in East Africa, 77% (27/35) of outbreaks began  
337 between November and January; for southern Africa, 80% (8/10) began between March

338 and June; for West Africa, 92% (12/13) began between July and October; for the  
339 Arabian Peninsula, 93% (13/14) began between August and October; and for North  
340 Africa, 67% (6/9) began between September and October.




341  
342 **Fig 2. Regional map of countries exposed to RVFV infection based on findings of**  
343 **studies included in the systematic review.** Countries were categorized as to whether  
344 there was evidence of human, animal, or insect RVFV infection during the 1999-2021  
345 era.  
346

347 Maps in Figs 3 and 4 show the sub-national administrative regions where acute  
348 human and animal cases were reported during the earlier (1999-2010) or latter (2011-  
349 2021) halves of our study period, or both. The countries with multiple repeated human  
350 outbreaks across both early and later time intervals were Kenya (n=4), Mauritania (n=5),  
351 South Africa (n= 4) and Madagascar (n= 2). S5 Table lists dates, place names, GPS




352 locations, reported human case counts, incidence rates per 100,000, reported numbers  
353 of deaths, and estimated case fatality risks.



354

355 **Fig 3. Sub-national administrative regions experiencing acute human cases of**  
356 **RVF during the years 1999-2021** Locations are shaded according to whether they  
357 experienced outbreaks before or after 2011, or if they had outbreaks during both  
358 periods.  
359

360 In terms of epizootic activity, Fig 4 highlights the countries that experienced repeated  
361 acute RVF outbreaks among animals during one or both decades of the 1999-2021  
362 period. These were Kenya (n= 4), Madagascar (n= 2), Mauritania (n= 6), Mayotte (n=  
363 2), Mozambique (n=2), Senegal (n=3), and South Africa (n=4).



364

365 **Fig 4. Sub-national administrative regions experiencing acute animal cases of**  
366 **RVF during the years 1999-2021** Locations are shaded according to whether they  
367 experienced outbreaks before or after 2011, or during both periods of time.  
368

#### 369 **Serosurveys of human and animal RVFV exposure**

370 Of the population surveys performed during interepidemic periods to detect  
371 evidence of prior local RVFV circulation, 50 surveyed human populations, 79 surveyed  
372 livestock populations, and 23 tested local wild animals. Of these, eight jointly surveyed  
373 both humans and livestock, and nine surveyed both wildlife and livestock. A summary of  
374 available diagnostic assays used to identify anti-RVFV antibodies is presented below in  
375 Table 1.

376

377

378 **Table 1. Currently used serologic assays for detection of RVFV exposure in**  
 379 **humans.**

<b><i>In-house Methods</i></b>			
<b>Method</b>	<b>Publication</b>	<b>Target antibody</b>	<b>Brief description</b>
ELISA <sup>1</sup>	LaBeaud et al. 2008 [68]	IgG	Indirect ELISA for presence of anti-RVFV IgG antibodies at Stanford University School of Medicine using inactivated MP-12 strain for coating antigen. Validated in humans
ELISA DIVA <sup>1,2</sup>	McElroy et al. 2009 [69]	IgM or IgG	Two parallel ELISA to distinguish naturally infected from vaccination. Validated in goat and humans. Does not distinguish IgG vs IgM
ELISA <sup>1</sup>	Paweska et al. 2005 [70]	IgM and IgG	IgG sandwich and IgM capture assay that uses irradiated whole virus for antigen. Validated in humans
ELISA <sup>1</sup>	Paweska et al. 2007 [71]	IgG	Antigen made using recombinant N protein. Validated in humans
ELISA <sup>1</sup>	Jansen Van Vuren and Paweska, 2009 [72]	IgM and IgG	Indirect ELISA for IgG and IgM separately. Antigen made using recombinant N protein. Validated in humans
VNT <sup>3</sup>	Winchger Schreur et al. 2017 [73]	All neutralizing antibodies	Uses a virulent RVFV that expresses enhanced green fluorescent protein. Not species specific
Optical Fiber Infrasond Sensor	Sobarzo et al. 2007 [74]	IgG	Sandwich based ELISA and antigens are immobilized on an optical fiber that makes it more sensitive. Validated in humans
Luminex DIVA <sup>2</sup>	Van der Wal et al. 2012 [75]	IgM and IgG	Bead based assay that detects RVFV Gn and N proteins
<b><i>Commercially available methods</i></b>			
	<b>Manufacturer</b>		
IFA <sup>4</sup>	EUROIMMUN	IgG	Approved for clinical testing
IFA <sup>4</sup>	EUROIMMUN	IgM	Approved for clinical testing
ELISA <sup>1</sup>	Biological Diagnostic Supplies Limited	IgM and IgG	Approved for clinical testing
ELISA <sup>1</sup>	ID-Vet	IgG	Competitive ELISA kit for the detection of anti-RVFV antibodies in serum or plasma. Multi-species that includes human validation

ELISA <sup>1</sup>	ID-Vet	IgM	IgM Antibody Capture ELISA for the detection of anti-nucleoprotein IgM antibodies. Validated for ruminant serum and plasma
--------------------	--------	-----	--

380 <sup>1</sup>ELISA: enzyme-linked immunoassay <sup>2</sup>DIVA: Differentiating Infected from Vaccinated  
381 Animals <sup>3</sup>VNT: Viral neutralization test; <sup>4</sup>IFA: immunofluorescent antibody

382  
383 Adapted from Petrova, et al., BMJ Glob Health 2020,doi:10.1136/bmjgh-2020-002694  
384 [76] under Creative Commons CC BY-NC

385  
386 In several animal surveys performed during interepidemic periods, low rates of  
387 livestock and wildlife anti-RVSV IgM seropositivity or IgG seroconversion were detected  
388 in areas of Namibia, Senegal, South Africa, and Kenya [47, 77-79] suggesting  
389 unsuspected ongoing RVSV transmission in those locations without detection of  
390 concurrent clinical RVF cases. Also of note were animal studies that showed serologic  
391 evidence of RVSV circulation among animals or humans within areas that had no prior  
392 evidence of RVSV circulation. These were: among animals only, in Libya [OIE], Tunisia  
393 [80], and Western Sahara [81] in North Africa, but in either humans or animals in Sierra  
394 Leone [36], Côte d'Ivoire [82], Djibouti [83], Rwanda [84, 85], and eSwatini [OIE], i.e.,  
395 geographical areas in sub-Saharan Africa with no previously documented transmission.  
396 Anti-RVSV antibody testing of human patients in health centers in Ghana [86] and  
397 Jordan [55] did not detect evidence of local exposure.

### 398 **RVSV lineage studies**

399 Twenty-six papers reported on sequence analysis of RVSV isolates from recent  
400 and more distant outbreaks in an attempt to identify the geographic extent of specific  
401 viral lineages in circulation at the time. Although variants have been seen to cluster in  
402 East African, West African, and Southern African groupings, the results from different

403 studies are heterogeneous, and nomenclature for these variants has not yet been  
404 standardized. The included studies on strain and lineage are summarized in S6 Table.  
405 Differences are noted depending on the segment(s) of the viral genome analyzed, the  
406 clustering algorithm used, and the reference isolate used as a 'type specimen' for  
407 comparison.

408         Sub-lineages of the Eastern group were found in the 1997-1998 Kenya/Tanzania  
409 RVF outbreak, as well as the 2000-2001 Saudi Arabia/Yemen outbreak [87, 88]. These  
410 were most similar to the RVFV isolates from humans, animals and insects the Kenya  
411 2006-2007 epidemic (when variants termed Kenya-1, Kenya-2, and Tanzania-1 co-  
412 circulated) [87, 89]. Later 2008-2009 isolates from outbreaks in Comoros [90], Mayotte,  
413 and Madagascar [91, 92] were also from the Eastern group. Although Eastern African  
414 group isolates were recovered from Mauritania in 2010 [93] and Senegal in 2013 [94] in  
415 West Africa, outbreaks in these countries in other years have identified a separate West  
416 African lineage grouping of RVFV isolates [95, 96]. Grobbelaar and colleagues [97]  
417 have used the sequence from the viral Gn surface peptide to compare 198 isolates  
418 recovered between 1944-2010 from across Africa and the Arabian Peninsula, and have  
419 defined 15 different lineages, which they have labeled A through O. South African  
420 isolates in 2008 were grouped in the C lineage, related to the Kenya-1 lineage.  
421 However, during 2009-2011, South African isolates were predominantly found in a new,  
422 separate lineage H [98], while one isolate in Northern Cape Province was from lineage  
423 K. Lineage K was later identified in a small South African outbreak in 2018 [99], and in  
424 an RVFV-infected Chinese expatriate working in Angola in 2016 [100].

425 **Table 2. Rift Valley fever virus lineage determinations for isolates recovered in**  
 426 **recent epidemics, based on cluster analysis of gene sequences for the viral Gn**  
 427 **surface protein. (Based on Grobbelaar, et al. 2011 [97])**  
 428

Grouping	Grobbelaar System	Year	Country	Species	Lineage Notes	Reference
<b>East African</b>	lineage C	2000-01	Saudi Arabia, Yemen	Human	Very similar to 1997-98 isolates/variants Kenya-1, Kenya-2, and Tanzania-1	[87, 88]
	lineage C	2006-07	Kenya	Humans, Livestock, Vectors		[87, 89]
	N/A	2007	Comoros	Humans	Similar to Kenya 2006-7	[90]
	lineage C		Madagascar			[91, 92]
<b>West African</b>			Mauritania, Senegal, Niger		Related to Kenya-1 lineage	[95, 96]
<b>Southern African</b>	lineage C	2008-09	South Africa			[97]
	lineage H	2009-11	South Africa			[101]
	lineage K	2009-11	South Africa			[101]
	lineage K	2018	South Africa			[99]
	lineage K	2016	Angola/China			[100]


429

430 **Human outbreak characteristics**

431 During human outbreaks, surveillance and reporting efforts varied greatly from  
 432 location to location. We observed that among human outbreak reports, the calculated  
 433 incidence rates of probable or confirmed human RVFV infections among local or  
 434 regional residents varied between 0.01 and 91 per 100,000 population, with a median  
 435 value of 2.5. Case fatality risks for these probable or confirmed cases varied from zero  
 436 to 65% (median = 14.3%) in locations where more than one case was reported (n= 107  
 437 locations from 41 publications, see S5 Table).

438 The cumulative human exposure to RVFV infection is also heterogeneous across  
439 locations. In endemic areas, this cumulative exposure is usually estimated based on the  
440 population prevalence of human anti-RVFV IgG seropositivity. Among the 25 well-  
441 designed population-based serosurveys (scored as having low risk-of-bias) among our  
442 included reports (n= 44), IgG seroprevalence during interepidemic periods ranged from  
443 (0.15%) in Madagascar in 2014-2015 [40] to 22% in eastern Kenya in early 2006 [102]  
444 and again in 2013-2014 [103], with an overall median intra-epidemic value of 5.2% (IQR  
445 1.8% - 13%) seropositivity across all 25 surveys.


446  
447



448  
449 **Fig 5. Acute human RVF events per year during 1999-2021, by geographic regions**  
450 **across Africa, the Indian Ocean, and the Arabian Peninsula**  
451

452 Acute human RVF outbreaks were reported across Africa, the Arabian Peninsula, and  
453 the Indian Ocean from 2000-2021 (Fig 5). The highest number of reported human RVF  
454 events occurred in 2006-7, starting in East Africa, moving to Sudan (North Africa) and  
455 then to the islands in the Indian Ocean during 2007-2008, as part of an evolving  
456 epidemic and epizootic of the East African RVFV lineage. In East Africa, new RVFV  
457 outbreaks have recurred annually since 2016, whereas no new human cases have been  
458 reported in the Arabian Peninsula since 2001. RVF flared in southern Africa in multiple  
459 episodes between 2008 and 2011 and West African countries Mauritania and/or  
460 Senegal have reported cases across multiple years, 2003. 2010, 2012-3, 2015-6, and  
461 again in 2020.

462



463



464 **Fig 6. Acute animal RVF events per year during 1999-2021, by geographic regions**  
465 **across Africa, the Indian Ocean, and the Arabian Peninsula**  
466

467 A larger number of acute animal RVF events (N = 273), compared to human events (N  
468 = 132), was reported during the 1999-2021 period studied. The reported animal events  
469 in southern Africa (N= 31) and in the Indian Ocean islands (N= 19) were concentrated  
470 during the 2008-2011 period (Figs. 5 and 6). By contrast, animal events in West Africa  
471 and East Africa were reported during most years of the targeted time interval  
472 (cumulative N= 80 and N=118, respectively), with the highest yearly tally being 41  
473 reported events in 2018 (Fig 6). No animal event was reported in the Arabian Peninsula  
474 after 2010, while only a low number of events were reported in Central and North  
475 African countries between 2002-2019 (cumulative N= 8 and N= 9, respectively; Fig. 6).

476 Of 28 papers that reported both human and livestock data, 17 contained  
477 information on concurrent co-local RVF epidemic and epizootic activity. These reports  
478 documented combined human/animal RVFV transmission events in Saudi Arabia [104,  
479 105] and Yemen [106] in 2000-2001; in Egypt [107] and Mauritania [108] in 2003; in  
480 Kenya [5, 89] and Tanzania [89, 109] in 2006-2007; in Mauritania in 2010 [93, 110] and  
481 again in 2012 [111]; in Senegal in 2013-2014 [94]; in Niger [96] and in Uganda [112] in  
482 2016; and in Kenya [113], Mayotte [114], and South Africa [115] in 2018.


483 **Evidence of vector presence and competence for interepidemic RVFV**  
484 **transmission.** In S7 Table we summarize 31 published studies from 1999-2021 that  
485 tested insect vector species for RVFV infection potential. Our systematic review  
486 identified 21 locations with RVFV-positive vectors, including mosquitos from *Aedes*,  
487 *Culex*, *Anopheles*, and *Mansonia* spp. and from *Hyalomma* spp. ticks (Fig. 2). Notably,

488 in 6 out of 10 trapping surveys performed during interepidemic years in endemic zones,  
489 live RVFV or RVFV RNA was detected in captured vector mosquitoes or ticks [116-121].  
490 As the lifespan of mosquito vectors is relatively short, the presence of RVFV viral RNA  
491 in these vectors likely represents sustained circulation in each of the given locations.

492 **Human risk of RVFV-related disease.** Among our included studies from the  
493 systematic review, 84 reports assessed human risk factors for RVFV exposure. The  
494 factors most commonly assessed were occupation (33 papers), gender (30), age (89),  
495 contact with animals (38), travel (15), as well as proxies for mosquito exposure such as  
496 work or residence in proximity to water sources (12), and personal behaviors related to  
497 mosquito avoidance (29).

498 Quantitative assessment of the role of gender involved estimation of chances for  
499 RVFV exposure by men and women in endemic settings. There were 31 studies that  
500 reported RVFV exposure (cases or anti RVFV seropositivity) according to gender (Fig  
501 7). There was moderate heterogeneity among these studies ( $I^2 = 39\%$ ), and random  
502 effects modeling estimation yielded a summary pooled OR estimate of 1.41 (CI<sub>95%</sub> 1.24,  
503 1.60,  $p < 0.001$ ) for males vs. females in their exposure rates (Fig 7). This value, based  
504 on studies from 1999-2021, remained very similar to that calculated by Nicholas and  
505 colleagues [64] (OR = 1.36) in their meta-analysis of studies from 1984-2011.

## Male:Female Odds Ratio for Human RVFV Infection



506


507 **Fig 7 Meta-analysis of the impact of human gender on odds of RVFV exposure in**  
 508 **at-risk populations**

509

510 **Greater human risk associated with animal contact.** Eleven well-structured  
 511 human surveys (having moderate to low risk of bias, i.e., LQAT scores  $\geq 6$ ) compared  
 512 rates of RVFV exposure among local residents according to the extent of their daily  
 513 contact with animals, particularly ruminant livestock. Heterogeneity was high among  
 514 these studies ( $I^2 = 68\%$ ). However, random effects meta-analysis, summarized in the  
 515 Forest plot in Fig 8, yielded a summary OR estimate signifying a 46% increase in the  
 516 odds of RVFV exposure among people with regular animal exposure (random effects  
 517 model pooled OR = 1.46,  $CI_{95\%} = 1.09, 1.94, p = 0.01$ ) in at risk populations. In separate


518 task analyses, S1-S3 Figures show Forest plots for summary estimates of associations  
 519 between butchering, sheltering, and milking livestock activities and risk of RVFV  
 520 exposure among at-risk populations. The estimates were: for butchering, OR = 3.7  
 521 (CI<sub>95%</sub> = 2.5, 5.4, p < 0.001, I<sup>2</sup> = 75%); for sheltering, OR = 3.4 (CI<sub>95%</sub> = 2.1, 5.4, p <  
 522 0.001, I<sup>2</sup> = 57%); and for milking, OR = 5.0 (CI<sub>95%</sub> = 2.8, 8.8, p < 0.001, I<sup>2</sup> = 77%),  
 523 indicating significantly higher risk with these exposures. Among these pooled studies,  
 524 there was no evidence of publication bias (by funnel plot or by Eggar’s statistic). There  
 525 were no yearly trends in exposure effects, nor did sensitivity analysis indicate evidence  
 526 of any single dominant study for each exposure-related outcome.

## Odds Ratio of RVFV Infection When Exposed to Animals



527  
 528 **Fig 8 Meta-analysis of the impact of animal exposure on odds of RVFV exposure**  
 529 **in at-risk populations.**

## Odds Ratio of RVFV Infection When Handling Abortus



530  
531

532 **Fig 9 Meta-analysis of the impact of handling RVF-related animal abortions on**  
533 **odds of human RVFV exposure in at-risk populations**

534  
535           Thirty-nine included studies assessed human RVFV-infection risk factors related  
536 to different animal exposures and 17 of those studies linked animal exposures to acute  
537 human RVFV infections (S8 Table). In meta-analyses performed according to specific  
538 animal contact tasks, handling aborted material during an RVF outbreak had the  
539 greatest pooled odds ratio of human infection (random effects model pooled OR = 3.65,  
540  $CI_{95\%} = 2.32, 5.73, p < 0.001, I^2 = 73\%$ ).

541           Our survey also provided individual reports of an additional 21 significant animal  
542 contact risk factors that had not been commonly assessed. In a study in Tanzania  
543 during the 2006-2007 East Africa outbreak, 40% of 115 RVFV cases reported having  
544 contact with animal products including meat and milk from sick animals, compared to  
545 just 28% of the cases reporting having slaughtered an animal [122]. Specifically,

546 consumption of meat from sick animals was associated with a nearly four-fold increased  
547 risk of RVF-associated death during the 2006-7 outbreak in Kenya [68].

548 **Occupational and socioeconomic factors associated with RVFV exposure.**

549 Our systematic review identified seven studies overall that found statistically significant  
550 risks related to socioeconomic factors such as education level, ethnicity, and household  
551 size. Briefly, the less wealthy and less educated were overrepresented among RVFV  
552 exposed people (S9 Table).

553 Forty-five of the 506 papers assessed occupation as a human risk factor and 14  
554 references found occupation to be a statistically significant factor (S10 Table). For  
555 clarification, those who were classified as ‘herders’ may not necessarily live a pastoralist  
556 lifestyle, so they have been given separate status. We found three studies that reported  
557 high seroprevalence among “housewives”, which might be explained by their frequent  
558 handling of raw meat and animal products for cooking.

559 **Risk Factors for RVF severity.** Out of the 135 included papers assessing  
560 human RVFV exposure and disease, 12 presented data on human risk factors  
561 associated with more severe RVF disease presentation (S8 Table). Persons with animal  
562 contact were usually more likely to have had severe disease, [21, 123, 124]. In  
563 outbreaks in Kenya [123, 124], specific animal contact activities such as handling or  
564 consuming products from obviously sick animals (OR for more severe disease = 2.53,  
565  $CI_{95\%} = 1.78, 3.61$ , population attributable risk percentage [PAR%] = 19%) and touching  
566 an aborted animal fetus (OR = 3.83,  $95\% CI_{95\%} = 1.68, 9.07$ , PAR% = 14) were strongly  
567 linked to risk of severe rather than mild human RVF disease. Older age and death of a  
568 family member were also linked to more severe human disease [123]. In Sudan, males

569 aged 15-29 years were overrepresented among patients who presented with severe  
570 disease, as compared to females of the same age [125]. Environmental factors, such as  
571 excess rainfall and muddy soil linked to emergence of mosquito blooms have also been  
572 linked to severe human disease in both Sudan and Kenya [126, 127].

573       Severity of human RVF was associated with the presence of concomitant co-  
574 infections. A fatal outcome in a travel related case was attributed to the presence of  
575 concurrent hepatitis A virus infection [45]. Additionally, a study in South Africa during the  
576 2010 RVFV outbreak indicated that existing HIV-positive infection status was associated  
577 with risk of the encephalitic form of RVF disease [128], a finding similar to experience  
578 among HIV-infected patients in Tanzania in 2007, where all patients with HIV-positive  
579 status developed encephalitis, and of whom 75% died [122].

580       Four studies performed in three countries (Kenya, Sudan, Saudi Arabia),  
581 examined the risk factors linked to death from RVF. In Kenya in 2007, consuming and  
582 handling products from sick animals and village and district location were linked to risk  
583 of death (OR = 3.67, CI<sub>95%</sub> = 1.07, 12.64, PAR% = 47%) [124, 129]. In Saudi Arabia, a  
584 retrospective analysis of the 2000-2001 outbreak showed that specific clinical signs  
585 were independently linked to death. These included jaundice, bleeding, and neurologic  
586 symptoms ( $P < 0.0002$ ) [130]. One study demonstrated an increased level of RVFV  
587 replication in fatal RVFV [131].

588       **Risk factors for animal RVFV outbreaks.** Because human risk of RVFV  
589 exposure is closely associated with the local presence of infected livestock, we  
590 reviewed factors related to animals' risk of RVFV infection.

591           *Herd Immunity Levels.* Our systematic review included results from 174 animal  
592 studies, in which 144 tested domestic livestock and 26 tested wild animals for RVFV  
593 exposure and/or acute infection. Of all livestock studies included, 32 were conducted  
594 during an active epizootic, 10 were conducted just after an outbreak in the post-  
595 epidemic phase, and 97 were conducted during interepidemic years. For wildlife  
596 surveys, 5 were carried out during an active epizootic, 5 were done in the post-epidemic  
597 phase, and 14 were performed during interepidemic periods. Of all animal risk factors,  
598 sex and age were the most studied, and older animals and those that had lived through  
599 outbreaks were more likely to have been exposed. A summary of livestock risk factors is  
600 presented in S11 Table.

601           *Herd Level Risks.* For herd level risks, the observed effects of herd size has  
602 varied across studies. A 2013-2014 study in a high risk area of Kenya showed that  
603 medium sized herds of 50-100 animals had a significantly higher seroprevalence  
604 compared to small herds (< 50 animal) or very large herds (>100 animals) [132], though  
605 this did not account for the differences in animal rearing strategies dependent on herd  
606 size. The statistical significance of herd size was lost when village was accounted for as  
607 a random effect [74]. In Tunisia, the first assessment of serology in camels in 2017-  
608 2018 showed that camels living in smaller herds intended for meat production had a  
609 higher seroprevalence than those used for military purposes or tourism. Additionally,  
610 this study found that camels that had contact with ruminants had significantly higher  
611 rates of RVFV exposure [80].

612           The differing levels of RVFV susceptibility across livestock species (S11 table)  
613 further complicates the herd immunity threshold related to animal-to-human RVFV



614 spillover. Additionally, livestock had variable contact with other livestock from  
615 neighboring herds and regions. An extensive social contact analysis from the 2008-  
616 2009 Madagascar outbreak showed that bartering practices, in which cattle can have  
617 multiple contacts within a village, was a significant seroconversion risk factor [133].  
618 Such bartering practice can support for inter-village RVFV circulation, whereas formal  
619 trade networks or cross-border smuggling were more likely to be responsible for trans-  
620 national spread [134, 135].

621 *Individual Animal Risks.* For individual-level animal risk, studies examining cattle  
622 had the most significant findings. Abortion was the most recognized clinical sign  
623 associated with RVFV infection and recent abortion was significantly associated with  
624 RVFV exposure [136]. This experience was the first to identify the 2018 RVFV  
625 outbreaks in Kenya when farmer-reported surveillance was implemented [126]. None of  
626 the included studies found an association between underlying animal body condition  
627 and RVF risk.

628 **Wild animals' role in RVFV transmission.** RVFV has been found in a variety of  
629 wild mammals [48]. Wild ruminants, especially buffalo, have been found to have  
630 significant herd seroprevalence during inter-epidemic period in endemic areas [46, 137,  
631 138]. For species-specific risk factors, interspecific network centrality, home range and  
632 reproductive life-history traits were associated with RVFV occurrence. S12 Table  
633 summarizes the wild animal seropositivity and acute infections identified in our literature  
634 review.

635 **Animal Vaccination.** Among the included papers in this review, we identified 17  
636 studies in six countries that included vaccinated animals. Countries that had vaccinated


637 cattle, sheep, or goats for RVFV were Kenya, Tanzania, South Africa, Egypt, and Saudi  
638 Arabia [5, 139-143]. In Egypt, between 2013 and 2015, seroprevalence of anti-RVFV  
639 was 14.9% among immunized cattle, compared to 7.9% among unimmunized cattle  
640 [144]. Although livestock are required to be vaccinated before they are exported to  
641 Saudi Arabia, a study at a livestock quarantine facility in Djibouti found an anti-RVFV  
642 IgM-positive seroprevalence of 1.2% in sheep and goats (small ruminants grouped as  
643 'shoats') and 0.3% in cattle [139, 145]. A 2009 study in Mecca, Saudi Arabia found  
644 55.8% anti-RVFV IgG in ostensibly vaccinated sheep, but still found a 2.6% rate of IgM  
645 positivity, indicating possible ongoing circulation (despite herd vaccine status) or recent  
646 vaccination[146].

647 **Additional considerations for RVF risks.** The range of RVFV is expanding,  
648 and it appears to travel well [39, 147, 148]. In endemic countries, internal travel to or  
649 from outbreak epicenters is typically included in suspect case definitions. A recent  
650 review by Grossi-Soyster and LaBeaud [149] has highlighted the risk of RVFV  
651 transmission to travelers, and although most travelers will not have direct contact with  
652 livestock, their mosquito exposure behavior needs to be assessed.

653 **Reported surveillance methods** in animal, humans or vectors are summarized  
654 in S13 Table. Our review revealed 52 papers specifically reporting on RVFV  
655 surveillance. Their methods are not uniformly implemented, but include: i) leveraged  
656 RVFV testing of samples taken during surveillance for other diseases such as malaria,  
657 dengue, HIV, and Lassa fever [38, 150-152]; ii) the use of sentinel livestock herds in  
658 high-risk areas; iii) increased case surveillance based on monitoring of weather-related  
659 early warning signs; and iv) international collaborations with neighboring regions to

660 conduct surveillance. These surveillance systems do not necessarily operate in parallel,  
661 but instead may overlap and may only be implemented at times of perceived increased  
662 risk.

663 Fig 10 depicts the different types of early warning and surveillance systems and  
664 their relative certainty. S13 table further summarizes available information from open-  
665 source platforms on the early warning and surveillance systems used for RVFV  
666 transmission during 1999-2021.



667  
668 **Fig 10 Progressive scale of surveillance that can be used to indicate an impending RVFV disease**  
669 **outbreak**

670 Republished with permission of The National Academies Press, from *Under the Weather:*  
671 *Climate, Ecosystems, and Infectious Disease* (2001), Chapter 7: Towards the Development of  
672 Disease Early Warning Systems. P. 87; permission conveyed through Copyright Clearance  
673 Center, Inc. under license ID #1142222

674  
675 **RVFV Diagnostics.** When implementing surveillance for detecting RVFV  
676 transmission, one major constraint is the limited availability of accurate diagnostics in  
677 places where RVF disease occurs. For both human and animals, reliance on a clinical

678 presentation to prioritize RVFV testing is complicated by the significant clinical  
 679 diagnostic overlap with other febrile infection syndromes.

680 Although detection of circulating RVFV RNA by RT-PCR can be a definitive  
 681 diagnosis of active infection, because the human and livestock viremic period is typically  
 682 only 4-6 days (up to 14 days if hemorrhagic human disease), serologic testing is more  
 683 extensively used to investigate the epidemiology of recent and past infection. We  
 684 extracted data from 207 included review reports on the type of assays recently  
 685 employed for diagnosis of acute RVF. No studies tested livestock and wild animals  
 686 together for acute infection. The assays used to detect acute RVFV infections are  
 687 summarized in Table 3.

688

689 **Table 3: Summary of acute diagnostic assays employed in included studies, by**  
 690 **species**

Number of Included Studies that Used the Following Methods for Detection of Acute RVFV Infection												
Species	IgM	IgM, direct <sup>1</sup>	IgM, PCR	IgM, PCR, direct <sup>1</sup>	IgM, PCR IgG SC <sup>2</sup>	IgM, IgG SC <sup>2</sup>	PCR IgG SC <sup>2</sup>	Direct <sup>1</sup> only	PCR only	PCR, direct <sup>1</sup>	IgG SC <sup>2</sup> only	Total
Livestock	26	0	4	0	1	3	2	0	5	0	3	44
Humans	21	2	23	4	2	0	0	2	9	1	0	64
Humans, livestock	1	1	5	3	1	0	0	0	1	0	0	12
Humans, livestock, wildlife	0	0	0	1	0	0	0	0	0	0	0	2
Wildlife	0	0	1	0	0	0	0	1	0	1	1	4
Method Total	48	3	33	8	4	3		3	15	2	4	

691 <sup>1</sup>Direct: Direct detection methods include immunofluorescence assay, cell culture (virus  
 692 isolation), electron microscopy, and immunohistochemistry

693 <sup>2</sup>SC: IgG Seroconversion of IgG (positive IgG during the study period AND a previously  
694 documented negative status from the same individual)

695  
696  
697  
698

## DISCUSSION

699           During RVF epidemics, assessment of incidence, prevalence, and associated  
700 risk factors for infection are often based on case series of suspected patients, rather  
701 than well-designed, population-based surveys that enumerate laboratory-confirmed  
702 cases vs. non-cases. Epidemic and epizootic outbreak surveys are further hampered by  
703 limited access to the affected rural communities, which are often experiencing severe  
704 flooding caused by excessive rainfall, and very limited access to diagnostic testing. In  
705 addition, survey incidence/prevalence calculations may be imprecise because of lack of  
706 accurate census information. As a result of these factors and the irregular frequency of  
707 disease outbreaks, the epidemiology of RVFV transmission and the risk factors for  
708 RVFV-related human disease are not well defined. In some endemic areas, post-  
709 epidemic serosurveys have shown high community exposure to RVFV [68, 103, 151-  
710 156], even though symptomatic RVF had been only rarely reported by local health care  
711 services. Based on our consolidated picture of recent RVFV epidemiology and the  
712 knowledge gaps we have identified, future operational research and clinical trial design  
713 should consider the factors discussed below, with the understanding that currently  
714 available data have some significant limitations in accurately defining human risk for  
715 RVF.

716           Our review indicated that during the last two decades, new patterns of RVF  
717 epidemiology have emerged. The virus continues to expand its range across Africa  
718 countries and into new regions within endemic countries [58, 157]. It should be noted

719 that among studies that were technically excluded from our review, there were several  
720 completely negative serosurveys of animals performed in Spain [51], the Canary Islands  
721 [52], Mauritius [158], Zanzibar [159], South Korea [54], and Poland [53]. Expansion of  
722 RVFV transmission has been aided by livestock movement [34, 160-163] and the  
723 increasing frequency of extreme weather events involving heavy rainfall and flooding  
724 [59]. The discovery of vertical transmission within insect vector species other than  
725 floodwater *Aedes* spp. mosquitoes [164] indicates the existence of multiple pathways for  
726 local RVFV persistence in different ecosystems during time periods that are in between  
727 recognized outbreaks. An additional non-vector route of RVFV transmission to humans,  
728 i.e., maternal-fetal transmission, has also been identified recently [165-167], and it has  
729 been established that RVFV can be an abortifacient in humans [168]. Thus, treating  
730 RVF as a concern only during large scale outbreaks in known hotspots fails to capture  
731 the full burden of disease and its underlying transmission, and fails to detect new areas  
732 of emergence.

733 The limited understanding of transmission persistence during interepidemic  
734 periods is a major gap affecting our ability to control continued expansion of RVFV, both  
735 within and between countries. Prospective studies during interepidemic periods are  
736 needed to provide a deeper understanding of how RVFV survives then subsequently  
737 thrives in an endemic area. Study findings could then suggest how mitigation efforts,  
738 such as vaccination of high-risk humans, can be implemented even before existing  
739 surveillance systems detect an outbreak.

740 **Gap 1: Defining the likely interval between significant RVF outbreaks is**  
741 **challenging**, because without active case finding, passive detection is an imperfect

742 trailing indicator of transmission, as it requires a large enough case number of RVF  
743 clinical syndromes (e.g., abortions in livestock) to identify events. Over the last two  
744 decades, increased availability and sensitivity of RVFV diagnostic assays, including  
745 genotyping, have contributed to increased recognition of viral transmission. However,  
746 without baseline interepidemic surveys in both high and low risk areas it is not possible  
747 to determine whether RVF outbreak waves are due to persistence or to re-introduction  
748 of RVFV transmission. As the outbreak intervals for RVFV remain undefined, the lack of  
749 studies during interepidemic periods limit our ability to understand viral maintenance  
750 and make it difficult to qualify endemicity in support of mitigation efforts such as  
751 vaccination. More useful data would include concomitant active surveillance of vectors,  
752 livestock, and humans, and information on rainfall, temperature, mosquito larval  
753 sources, and the frequency of risk-related human behaviors. Because RVF livestock  
754 outbreaks are up to five times more likely to occur where outbreaks have previously  
755 occurred, and human outbreaks are more likely to occur in the same locations as  
756 livestock outbreaks [5, 169], areas with prior RVFV transmission shown in Figs. 3 and 4  
757 would be best locations to characterize interepidemic transmission.

758 Kenya, South Africa, Madagascar, and Mauritania have had recurrent human  
759 and domestic animal RVF outbreaks in the last two decades and are thus most likely to  
760 experience additional outbreaks in the near future. Notably, areas with recurrent  
761 outbreaks tend to have more robust surveillance which may account for the higher  
762 frequency of RVF detection in those locations (i.e., ascertainment bias). Based on  
763 findings identified in this systematic review, RVF can be more likely in a given location,  
764 compared to a similar nearby location due to many factors, including the total number of

765 susceptible hosts (influenced by herd immunity), the presence of wildlife reservoirs  
766 [170], the water retention properties of the soil and rainfall patterns [62], local cultural  
767 practices that may increase (consumption of blood) or decrease risk (refusing to eat  
768 meat from dead animals) [171], and mitigation efforts that persist between outbreaks.  
769 As these factors can be confounded, an in-depth understanding of RVFV epidemiology  
770 is needed to design investigations so that resources for operational research can be  
771 maximized.

772 **Gap 2: The unpredictability of livestock herd immunity** Current prevention  
773 and readiness efforts for RVFV outbreaks rely mostly on early warning prediction and a  
774 rapid livestock vaccination response, both of which occur with variable reliability.  
775 Recovery from infection and vaccination with live-attenuated vaccines are thought to  
776 result in lifelong neutralizing antibodies in livestock [172] and indeed, if enough livestock  
777 could be vaccinated for RVFV, then human spillover would be unlikely [173]. However,  
778 livestock within and between herds have a rapid turnover rate as animals are  
779 slaughtered and sold, or arrive naïve into the herd from new births or purchases.  
780 Additionally, livestock in RVFV endemic countries often live in close proximity to wild  
781 ruminant species that also acquire many naïve animals each breeding season. The  
782 logistics and current intermittent nature of domestic livestock vaccination campaigns, in  
783 the face of unknown baseline herd immunity levels, makes full reliance on reactive  
784 livestock vaccination a risky approach to RVFV public health control.

785 Most livestock animal studies have focused on cattle, sheep, and goat  
786 seroprevalence. Although some surveys have used power analysis to determine how  
787 many animals to sample from each species, many surveys have still opted for



788 convenience sampling, focusing either on sheep and goats, which are easier to handle,  
789 or on just cattle alone. The interpretation of such livestock prevalence surveys should  
790 be viewed with caution. Animal age is also likely to influence the results-- cattle and  
791 dairy animals tend to live longer than sheep or goats, so it can appear that their  
792 cumulative burden of exposure is higher. However, evidence of infection among  
793 younger animals does provide evidence for recent RVFV transmission activity, and  
794 increased seroprevalence between years can indicate an unrecognized outbreak. When  
795 multiple species are surveyed, rates should be calculated based on animal-years at risk  
796 and better attempts should be made to age animals based on their dentition. Factors  
797 that confound RVFV exposure risk should be captured, such as the wealth and  
798 knowledge of the farmer [113], area livestock density, and location-specific climate  
799 factors. We suggest factors such as nearby temporary and permanent water bodies,  
800 land use, mobility at peak mosquito biting times, housing conditions, and rearing  
801 strategy be combined with climate data to better discern spatial and temporal high-risk  
802 periods for livestock. This will be important in defining optimal locations for human  
803 vaccination trials.

804       As the previous systematic review by Clark, et al. [67] has highlighted, and as we  
805 found in our review, there are few studies that assess both human and animals from the  
806 same site at the same time. The high-risk periods for livestock and humans may not  
807 necessarily overlap, as livestock infections are undoubtedly driven by rainfall and  
808 mosquito blooms, but human outbreaks can also expand with increased slaughtering of  
809 sick animals and the increased presence of secondary mosquito vectors.

810 It is understood that livestock viral amplification is an important predecessor of  
811 human outbreaks. The greater number of acute animal events (N=273), compared to  
812 human events (N=132) identified in this review could be due to our increasing ability to  
813 detect smaller animal outbreaks or could represent our inability to reliably detect acute  
814 human cases associated with smaller animal outbreaks [174, 175]. After animal  
815 outbreaks are established, we recommend broad-based human outbreak investigations  
816 that include all community members, not just the high-risk individuals, i.e., all individuals  
817 who may have had contact with animal products from the affected herd, as well as  
818 those who do not own livestock but reside in areas within vector flight range.

819 **Gap 3: Differences in seasonality across endemic/enzootic locations.** As  
820 climate change modifies seasonal weather patterns, differences in outbreak incidence  
821 are becoming more prominent among at-risk locations, but these changes may make  
822 epidemics harder to predict. Eighty-nine (31%) of our included studies specifically  
823 mention flooding at the outbreak site. A defined “rainy season” and “dry season” in  
824 tropical locations can guide risk assessment, but it is not just rain that makes an  
825 outbreak more likely. Congregation of many susceptible hosts and large volume  
826 slaughtering of animals (for example, as part of religious or community festivals [146,  
827 176, 177]), an abundance of mosquito breeding containers (for example, in plastic  
828 trash) [178], large-scale animal movement [179], and low baseline herd immunity will  
829 increase the chance of RVFV outbreaks. Recent data-driven modeling efforts by  
830 Hardcastle and colleagues [58], incorporating environmental and human and animal  
831 census data at the district level, predict that outbreaks in southern and eastern Africa  
832 are most likely to occur in December through July, whereas risk in the Sahelian zone

833 will be higher in September through November [180]. Even within countries, seasonal  
834 rainfall can vary widely. For example, in western Kenya, August typically has above  
835 average rainfall while the remainder of the country remains dry [181]. Real-time regional  
836 level weather information must be considered to obtain adaptive implementation of  
837 mitigation efforts.

838 Pastoralist herds tend to have higher RVFV exposure, and this is influenced by  
839 the types of ecozones where the herds circulate. Pastoralists follow water and pasture  
840 availability as they become available in a seasonal cycle, which may involve movement  
841 through high-risk zones. As animal protein demand increases, mostly in urban centers,  
842 more livestock will be passing through areas that have previously experienced RVF  
843 cases, and in the presence of competent mosquito vectors. Recent infections are more  
844 common in nomadic herds compared to agro-pastoralist herds [182] and in herds with  
845 longer distance to travel to their night pens or to the nearest permanent water [82].  
846 Modeling of data from Senegal suggested that nomadic herd movements are sufficient  
847 to account for endemic circulation of RVFV, although the co-existence of *Aedes vertical*  
848 transmission cannot be ruled out [183].

849 In addition to climate, the variety of suitable hosts present in those areas will also  
850 vary from location to location. All potential wildlife reservoir species should be  
851 considered when comparing incidences between two geographically distinct areas  
852 because wild animals' behaviors and range is intimately tied to topography and  
853 resource availability. In Botswana, wildlife hunters' seroprevalence was 27% compared  
854 to a 3% community level exposure [35], showing that wildlife exposure may contribute  
855 directly to human burden independent of domestic livestock presence. This is further

856 illustrated by human case exposure in Angola without documented livestock exposure  
857 [100]. As RVFV can adapt to new ecological niches and utilize a wide variety of  
858 mammals to amplify itself, including common white-tail deer [184, 185], we caution not  
859 to make the assumption that wild animals' role in RVFV transmission will be similar  
860 between locations. All suitable wild animals, particularly wild ungulates, should in  
861 included in calculations of regional herd immunity and their interface with humans  
862 should be considered as a likely risk factor.

863 **Gap 4: Data challenges related to bias based on limited study designs and**  
864 **inconsistent reporting.** A systematic review by Bron and colleagues [186] has  
865 summarized the patchwork of data collected on RVFV epidemiology over the last  
866 century, and has highlighted the lack of standardized reporting as the major challenge in  
867 comparing data between locations. In our current systematic review, which focused  
868 solely on studies from the last two decades, we confirm that uneven reporting remains a  
869 significant problem. Improving study designs and sampling frameworks for RVFV is  
870 challenging, in part due to the lack of funding opportunities during interepidemic periods.  
871 In outbreak reports, uncertain levels of ascertainment bias and possible diagnostic  
872 misclassification, mean that case finding and resulting case counts have unclear  
873 accuracy. 'Population at risk' numbers used in incidence and prevalence calculations  
874 are often chosen based on outdated census data without true understanding of who is  
875 at risk within a community. With many smaller, low-budget, short-term studies (rather  
876 than large collaborative long-term efforts) the focus turns to identifying enough cases for  
877 a meaningful statistical analysis, which means that some studies will test only high-risk

878 individuals working with animals. This likely excludes vulnerable populations who have  
879 not yet been identified as being at high-risk.

880 Hospital-based surveys for hemorrhagic fever surveillance are an attractive tool  
881 because they do not require household field visits and blood samples are typically more  
882 available for testing [38, 40, 150-152, 187, 188]. Such sero-surveillance can be  
883 compared from year to year to gain retrospective insight on when transmission has  
884 occurred. However, as with most hospital-based studies, these efforts do not represent  
885 the population at large, so they likely underestimate true incidence and overestimate the  
886 percentage of cases with severe disease.

887 **Gap 5: Delineating human risk factors.** This meta-analysis of human risk  
888 factors across multiple 1999-2021 studies confirm the increased RVFV infection risk  
889 associated with male gender, general livestock care, contact with animal abortus,  
890 butchering animals, and milking risks, identified in previous reviews and meta-analysis  
891 [64, 189]. Not all of the studies in this systematic review were population-based, thus  
892 the variable reporting of associations having ‘statistical significance’ may be attributed to  
893 differences in study design, low sample size with lack of statistical power, and/or choice  
894 of target populations.

895 In most places where RVFV outbreaks occur, lack of health care infrastructure  
896 impedes detailed description of human disease signs and performance of laboratory  
897 studies (including assessment of viral load and immunologic responses to infection),  
898 which might be predictive of severe disease or death. It is possible that other health  
899 comorbidities, such as concurrent HIV or hepatitis, can influence the presentation of  
900 RVFV disease, but these associations have not yet been widely studied. Further

901 descriptions of the natural history of clinical and laboratory findings in human RVF are  
902 needed, and efforts should be made to fully assess the relative risks from direct (non-  
903 vector) animal exposures vs. mosquito vector-borne exposure. Frontline healthcare  
904 workers need to recognize when testing for RVFV infection is appropriate, based on  
905 patients' significant risk factors, and they should communicate frequently with local  
906 veterinary colleagues to identify high-risk transmission periods.

907         Most risk factor analyses rely on participant recall, risking recall bias, and it has  
908 been difficult to discriminate the risk of living in the presence of susceptible livestock  
909 from risk due to direct participation in husbandry activities or from risk due to local  
910 mosquito exposure (including variably zoophilic and anthropophilic mosquito species).  
911 Aside from animal rearing activities, the association of human risk with consumption of  
912 infected animal products is concerning, as this is practiced by a majority of human  
913 populations and the true infectivity by consumption is still not well understood. For  
914 example, consumption of raw milk is a now well recognized as an RVFV exposure risk  
915 factor [64, 189], but no previous studies have isolated RVFV from milk during outbreaks.  
916 Ongoing studies in Kenya (Gerken et al, unpublished), are conducting risk assessments  
917 in urban areas to distinguish consumption risk factors versus risk from livestock rearing  
918 activities common to rural areas.

919         RVF has been perceived as a disease of poverty, but this is likely due to its  
920 greater incidence recognized in rural areas. It is not known whether RVFV has an urban  
921 transmission cycle, and so far, the risk of RVF related to socioeconomic status (aside  
922 from having a pastoralist lifestyle) is poorly defined. Choice of occupation is intimately  
923 connected to socioeconomic status and this systematic review confirmed that the

924 highest-risk occupations are associated with livestock exposure. Even within  
925 occupational categories, differences in assigned tasks can carry differential risks [190].  
926 We combined common terminology for the same profession, for example,  
927 slaughterhouse and abattoir workers for our analysis; however, more specific factors  
928 such as size of the slaughterhouse, species slaughtered, and available personal  
929 protective equipment (PPE) are likely strong confounding factors.

930

931 **Gap 6: Need for consistent naming of RVFV lineages and strains.** A possible  
932 explanation for variation in RVF attack rates and disease severity, noted between  
933 locations and among different hosts, could be differences in RVFV strain virulence.  
934 Laboratory studies suggest some strain-specific differences in mortality in experimental  
935 animals [191]. However, the variability observed during natural outbreaks is likely due to  
936 site-related diagnostic misclassification of RVFV infection with erratic failure to detect  
937 milder cases of disease. Our systematic review aimed to capture strain- and lineage-  
938 specific effects; however, a meaningful analysis was obscured by inconsistent naming  
939 of lineages due to differences in the genetic sequences chosen to be studied and  
940 different approaches to sequence homology analysis. International harmonization of  
941 lineage identity and nomenclature will help to determine differential effects, if any, of  
942 individual RVFV lineages and strains. As with SARS-CoV2 variants, a naming scheme  
943 that does not rely on location may help to alleviate some of the disincentive and stigma  
944 for national governments to report acute cases and identify sequences of circulating  
945 genomes to identify sources of local introduction.

946           **Gap 7: Need for consistent RVFV testing frameworks.** As highlighted earlier,  
947 identification of RVFV outbreaks and determination of the endemic state of a country  
948 require consideration of the efficacy of surveillance efforts in place. Well organized and  
949 implemented surveillance systems provide the basis for understanding the epidemiology  
950 of RVFV and provide an opportunity to provide early warning and an opportunity to fill  
951 the gaps in current knowledge.

952           As RVFV diagnostics become more widely available, physicians in  
953 hyperendemic regions will be able to consider co-infection with RVFV in their differential  
954 diagnoses, especially for pregnant mothers who are at risk for abortion [168].  
955 Additionally, if hospitals are aware of current RVFV circulation in livestock, they can go  
956 on high-alert and intensify their screening of patients for RVF. However, the lack of  
957 specific medical therapeutics may dissuade clinicians from testing for RVFV and favor  
958 testing for more treatable conditions, notably malaria. As the recent experience with  
959 Ebola virus in West Africa has taught, compassionate care must be the cornerstone of  
960 outbreak response in order for the at-risk population to buy into control measures.  
961 Public health messaging that fuels despair results in massive underreporting,  
962 particularly if outbreaks become political [192].

963           There are concerted efforts to create a pan-viral hemorrhagic fever diagnostic  
964 assay. The Uganda Virus Research Institute (UVRI) in Entebbe has been implementing  
965 laboratory-based surveillance for viral hemorrhagic fevers (VHF) in Uganda since 2010,  
966 which includes testing for RVFV [193]. While this may help differentiate RVFV from  
967 other concerning viruses, we caution about the grouping of RVFV with other  
968 hemorrhagic fevers for surveillance purposes, as RVF-related hemorrhage in humans is



969 the rarest clinical manifestation, and the risk factors for other forms of RVFV-related  
970 disease are different.

971         Development of robust RVFV surveillance systems is complex, because both  
972 animals and humans display variably detectable disease outcomes when they become  
973 infected. Currently, most RVFV surveillance systems are engaged only in response to  
974 climate early warning systems and are focused on periods with high-risk for large scale  
975 outbreaks. We found that recent re-structuring of the FAO Global Animal Disease  
976 Information System (EMPRESi) has provided an open-source, easy to navigate platform  
977 for tracking reports of RVFV cases in member countries. Since 2004, the system has  
978 recorded 1,186 animal cases of RVFV, of which 1,175 were confirmed. This reporting  
979 system relies on mandatory reporting of acute cases by national authorities, the OIE,  
980 WHO, FAO field officers, and published reports such as those included in this review.  
981 However, this database excludes longitudinal seroconversions, and therefore, excludes  
982 evidence of sub-clinical transmission during interepidemic periods. Modeling  
983 approaches using only these data should consider this key missing piece in their  
984 assumptions. Although RVFV is a reportable disease in many of the affected countries,  
985 a system that relies on passive reporting is likely to miss areas of new emergence when  
986 viral activity is below the threshold to detect excess numbers of patients with the more  
987 obvious clinical signs of RVF. It should be noted that the partnership of a strong national  
988 veterinary service with close ties to a fully equipped national laboratory is crucial to any  
989 successful surveillance effort. If farmer-based cellphone reporting is to be successful at  
990 identifying RVF cases, farmers need to be sensitized to the greater goals of the system  
991 and incentivized to report. Overall, the ideal surveillance system for RVFV would utilize

992 aspects of each of the discussed surveillance types (Fig 10), focusing on sentinels and  
993 enhanced active case finding, including during interepidemic periods, and take into  
994 account regional differences in animal and human health systems. Since RVFV is a  
995 vector-transmitted disease, and a large proportion of the world has the potential for  
996 RVFV emergence, the management of RVFV surveillance efforts should be regionally  
997 collaborated and all RVFV-naive countries with large numbers of livestock should take  
998 into account past lessons about recent new geographic introduction as they prepare  
999 prevention and mitigation efforts for themselves [194-199].

1000         Post-epidemic performance analyses have found that the lead time given by  
1001 early warning systems may not be sufficiently long to prepare and vaccinate enough  
1002 livestock to contain an outbreak. Just as reliance on a passive surveillance system for  
1003 RVFV is likely to not be enough to detect outbreaks, sole reliance on a remotely sensed  
1004 early warning systems (EWS) should also be avoided. One major limitation of climatic  
1005 EWS is that they do not account for the effect of herd immunity, either through natural  
1006 infection or prior livestock vaccination. Livestock seroprevalence as high as 60% have  
1007 been captured in high risk areas [200] and up to 38% in areas that are not typically  
1008 classified as high risk, such as Chad [201]. The lack of outbreak detection, despite  
1009 seemingly high-risk weather conditions, can be explained both by the effect of herd  
1010 immunity and limitations of existing surveillance systems. With this current level of  
1011 performance, at-risk countries should not rely solely on early warning systems and  
1012 instead use them as part of integrated decision support tools, similar to those developed  
1013 for the greater Horn of Africa [202]. As RVFV outbreaks have often had an insidious

1014 onset, we recommend active case finding in high-risk areas in response to any of the  
1015 previously mentioned early warning signals.

1016 **Gap 8: Evolving better approaches to diagnostics.** Because arboviral  
1017 infections such as RVF often result in self-limited febrile syndromes with non-specific  
1018 signs and symptoms, isolated cases of infection are frequently misdiagnosed as malaria  
1019 in sub-Saharan Africa. This highlights the critical need for affordable and accurate point-  
1020 of-care diagnostics for RVFV [203-206]. In the majority of recent transmission surveys,  
1021 anti-RVFV IgM serology was used alone to define recent infection, and more humans  
1022 than animals were found to be positive. As commercial IgM ELISA tests are now more  
1023 widely available for livestock, this gap likely represents a lack of available resources,  
1024 either financial or logistical, for testing livestock for recent infection. For suspect acute  
1025 cases, IgM allows a wider window of detection than discovery of circulating virus or viral  
1026 RNA [207].

1027 Among the 95 studies that reported human serology, the methods for human  
1028 anti-RVFV antibody detection exhibited significant variability, with most studies relying  
1029 on tertiary reference laboratories for final diagnosis. Future efforts should focus on  
1030 increasing the number and capacity of local laboratories so that the burden of shipping  
1031 time and costs can be alleviated. The Covid-19 pandemic response has led to  
1032 expansion of molecular diagnostic capacity in many regions. In the aftermath of the  
1033 pandemic, these important logistical and laboratory resources should be leveraged to  
1034 include other viral diseases such as RVF.

1035 Serology serves as the basic approach for investigating individual and  
1036 community level risk factors as it can monitor changes in prevalence over time. Both

1037 enzyme-linked immunosorbent assays (ELISA) and viral neutralization tests (VNT) have  
1038 advantages and disadvantages. Identifying IgG-positive livestock by ELISA has often  
1039 been the first step in recognizing new areas of emergence [80, 208]. However, follow up  
1040 VNT should be used to confirm positive ELISA results in new locations, especially if the  
1041 seroprevalence is low (less than 1-2%) when misclassification due to false-positive tests  
1042 is of concern.

1043 **Gap 9: The need for One Health approaches for RVFV detection and**  
1044 **control.** Expanding RVFV surveys to include human community populations at-large  
1045 will identify risk associated with socioeconomic standing, while simultaneously detecting  
1046 patients with incident infections but without presently known risk factors. To fully  
1047 understand the ecology of local transmission such broad-based human studies need to  
1048 be conducted concurrently with robust animal surveys. Recent reviews and policy  
1049 papers in the human and animal health RVFV literature call for a greater emphasis on a  
1050 One Health management approach, both in research and control efforts [127, 209, 210].  
1051 A better understanding of viral transmission to all species during interepidemic periods,  
1052 with an improvement of diagnostic sampling frameworks, are within reach in the next  
1053 decade. Reaching an understanding of the herd immunity threshold for outbreak  
1054 initiation, the variability in case fatality risks, the contributions of vectors to both  
1055 asymptomatic and symptomatic human and animal infections, and the most influential  
1056 transmission pathways will take a collaborative effort among multiple disciplines and  
1057 public health sectors. The gaps presented here are based on a collated estimates of  
1058 recent RVFV transmission. The available case counts and serosurveys in this

1059 systematic review contribute to a body of evidence that can guide the way forward to  
1060 clinical testing of novel preventive and curative interventions.

1061         **Summary.** RVFV continues to transmit across Africa and nearby Indian Ocean  
1062 islands at a high rate, but at an irregular frequency. As previously noted, because of its  
1063 typical mosquito-borne re-emergent transmission, RVFV outbreaks often follow periods  
1064 of excess rainfall and local flooding, particularly in semi-arid regions. During the 1999-  
1065 2021 period studied in this review, animal and human outbreaks of RVF occurred at an  
1066 average rate of 5-6 events per year across the region. The range of transmission has  
1067 expanded, with human cases documented for the first time in Saudi Arabia, Yemen,  
1068 Comoros, Mayotte, Burundi, Niger, and Mali, and with re-emergence in Uganda after  
1069 multiple decades of no activity. Reported human RVF events were most common in  
1070 Mauritania, Kenya, Sudan, Madagascar, and South Africa, and each of these countries  
1071 experienced multiple epidemics since 1999. In districts or counties where human cases  
1072 were reported, the median attack rate was 2.6 per 100,000 (range 0.1 to 91), and  
1073 median case fatality was 14.1% of severe cases, highlighting the significant population  
1074 health burden of RVF.

1075         Experience with veterinary vaccines indicates that pre-event vaccination can  
1076 mitigate the spread of RVFV infection. Now that human vaccines are under  
1077 development, and their clinical testing and implementation should be guided by  
1078 particular focus on the high-risk subgroups (based on location and exposures) identified  
1079 in this review. Effective vaccine trials will depend on achieving accurate outbreak  
1080 predictions combined with efficient animal and human case surveillance systems.

1081

## 1082 **Acknowledgments**

1083 The authors would like to acknowledge the very helpful guidance provided by members  
1084 of the CEPI literature review advisory group: Dr. Brian Bird, Dr. Baptiste Dungu, Roice  
1085 Fulton, Dr. Jeroen Kortekaas, Dr. Paul Oloo, Dr. Janusz Paweska, Dr. Melinda Rostal,  
1086 and Dr. George Warimwe.

1087 We also acknowledge the assistance of RVFV research collaborators who provided  
1088 their unpublished survey data for inclusion in this study: Garja S. Suner, Pius S. Ekong,  
1089 Elysse N. Grossi-Soyster, Mabel K. Aworh, Yiltawe S. Wungak, Nanven A. Maurice,  
1090 Michael J. Ekong, and Bonto Faburay.

1091

## 1092 **Figure legends**

1093 **Fig 1. PRISMA systematic review flow diagram of data collection and evaluation**  
1094 Online searches for publications and data registers (left side flow) were supplemented  
1095 by governmental outbreak reports, non-indexed citations found in local archives, and  
1096 citations found within the reference lists of the papers that were reviewed (right side  
1097 flow). Data from one unpublished study were also included for evaluation.

1098  
1099 **Fig 2. Regional map of countries exposed to RVFV infection based on findings of**  
1100 **studies included in the systematic review.** Countries were categorized as to whether  
1101 there was evidence of human, animal, or insect RVFV infection during the 1999-2021  
1102 era.

1103  
1104 **Fig 3. Sub-national administrative regions experiencing acute human cases of**  
1105 **RVF during the years 1999-2021** Locations are shaded according to whether they  
1106 experienced outbreaks before or after 2011, or if they had outbreaks during both  
1107 periods of time.

1108  
1109 **Fig 4. Sub-national administrative regions experiencing acute animal cases of**  
1110 **RVF during the years 1999-2021** Locations are shaded according to whether they  
1111 experienced outbreaks before or after 2011, or during both periods of time.

1112  
1113 **Fig 5. Acute human RVF events per year during 1999-2021, by geographic regions**  
1114 **across Africa, the Indian Ocean, and the Arabian Peninsula**

1115

1116 **Fig 6. Acute animal RVF events per year during 1999-2021, by geographic regions**  
1117 **across Africa, the Indian Ocean, and the Arabian Peninsula**

1118  
1119 **Fig 7 Meta-analysis of the impact of human gender on odds of RVFV exposure in**  
1120 **at-risk populations**

1121  
1122 **Fig 8 Meta-analysis of the impact of animal exposure on odds of RVFV exposure**  
1123 **in at-risk populations.**

1124  
1125 **Fig 9 Meta-analysis of the impact of handling RVF-related animal abortions on**  
1126 **odds of human RVFV exposure in at-risk populations**

1127  
1128 **Fig 10 Progressive scale of surveillance that can used to indicate an impending**  
1129 **RVFV disease outbreak.** Republished with permission of The National Academies  
1130 Press, from Under the Weather: Climate, Ecosystems, and Infectious Disease (2001),  
1131 Chapter 7: Towards the Development of Disease Early Warning Systems. P. 87;  
1132 permission conveyed through Copyright Clearance Center, Inc. under license ID  
1133 #1142222

1134

1135

## 1136 **References**

- 1137 1. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health  
1138 problems. Arch Med Res. 2002;33(4):330-342. Epub 2002/09/18. doi: 10.1016/s0188-  
1139 4409(02)00378-8.
- 1140  
1141 2. CDC. Rift Valley Fever. Viral Hemorrhagic Fevers: Fact Sheets. 2021:1-3. Available  
1142 from <https://www.cdc.gov/vhf/index.html>
- 1143  
1144 3. Isaäcson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis.  
1145 2001;33(10):1707-1712. Epub 2001/10/12. doi: 10.1086/322620.
- 1146  
1147 4. WHO. Rift Valley Fever. WHO Fact Sheet No 207. 2018:1-5. Epub 19 Feb 2018.
- 1148  
1149 5. Munyua P, Murithi RM, Wainwright S, Githinji J, Hightower A, Mutonga D, et al. Rift  
1150 Valley fever outbreak in livestock in Kenya, 2006-2007. Am J Trop Med Hyg. 2010;83(2  
1151 Suppl):58-64. Epub 2010/08/13. doi: 10.4269/ajtmh.2010.09-0292.
- 1152  
1153 6. CDC. Outbreak of Rift Valley fever--Yemen, August-October 2000. MMWR.  
1154 2000;49(47):1065-1066.
- 1155  
1156 7. Woods CW, Karpati AM, Grein T, McCarthy N, Gaturuku P, Muchiri E, et al. An  
1157 outbreak of Rift Valley fever in Northeastern Kenya, 1997-98. Emerg Infect Dis.  
1158 2002;8(2):138-144. Epub 2002/03/19. doi: 10.3201/eid0802.010023.
- 1159  
1160 8. Daubney R, Hudson JR, Garnham PC. Enzootic hepatitis or Rift Valley fever: an  
1161 undescribed virus disease of sheep, cattle and man from East Africa. Journal of  
1162 Pathology and Bacteriology. 1931;34:545-579.
- 1163  
1164 9. CDC. Update: Outbreak of Rift Valley Fever - Saudi Arabia, August-November 2000.  
1165 MMWR. 2000;49(43):982-985.
- 1166  
1167 10. Golnar AJ, Turell MJ, LaBeaud AD, Kading RC, Hamer GL. Predicting the mosquito  
1168 species and vertebrate species involved in the theoretical transmission of Rift Valley  
1169 fever virus in the United States. PLoS Negl Trop Dis. 2014;8(9):e3163. doi:  
1170 10.1371/journal.pntd.0003163.
- 1171



- 1172 11. Iranpour M, Turell MJ, Lindsay LR. Potential for Canadian mosquitoes to transmit  
1173 Rift Valley fever virus. *J Am Mosq Control Assoc.* 2011;27(4):363-369. Epub  
1174 2012/02/15. doi: 10.2987/11-6169.1.
- 1175  
1176 12. Turell MJ, Dohm DJ, Geden CJ, Hogsette JA, Linthicum KJ. Potential for stable flies  
1177 and house flies (Diptera: Muscidae) to transmit Rift Valley fever virus. *J Am Mosq  
1178 Control Assoc.* 2010;26(4):445-448. Epub 2011/02/05. doi: 10.2987/10-6070.1.
- 1179  
1180 13. Turell MJ, Wilson WC, Bennett KE. Potential for North American mosquitoes  
1181 (Diptera: Culicidae) to transmit Rift Valley fever virus. *J Med Entomol.* 2010;47(5):884-  
1182 889. Epub 2010/10/14. doi: 10.1603/me10007.
- 1183  
1184 14. Gargan TP, 2nd, Clark GG, Dohm DJ, Turell MJ, Bailey CL. Vector potential of  
1185 selected North American mosquito species for Rift Valley fever virus. *Am J Trop Med  
1186 Hyg.* 1988;38(2):440-446. doi: 10.4269/ajtmh.1988.38.440.
- 1187  
1188 15. Turell MJ, Bailey CL, Beaman JR. Vector competence of a Houston, Texas strain of  
1189 *Aedes albopictus* for Rift Valley fever virus. *J Am Mosq Control Assoc.* 1988;4(1):94-96.
- 1190  
1191 16. Chengula AA, Mdegela RH, Kasanga CJ. Socio-economic impact of Rift Valley  
1192 fever to pastoralists and agro pastoralists in Arusha, Manyara and Morogoro regions in  
1193 Tanzania. Springerplus. 2013;2:549. Epub 2013/11/21. doi: 10.1186/2193-1801-2-549.
- 1194  
1195 17. Holleman C. The socio-economic implications of the livestock ban in Somaliland.  
1196 Food Early Warning System, Assessment Mission to Somaliland. FEWS NET, Nairobi  
1197 2002.
- 1198  
1199 18. Muga GO, Onyango-Ouma W, Sang R, Affognon H. Sociocultural and economic  
1200 dimensions of Rift Valley fever. *Am J Trop Med Hyg.* 2015;92(4):730-738. Epub  
1201 2015/02/18. doi: 10.4269/ajtmh.14-0363.
- 1202  
1203 19. Rich KM, Wanyoike F. An assessment of the regional and national socio-economic  
1204 impacts of the 2007 Rift Valley fever outbreak in Kenya. *Am J Trop Med Hyg.* 2010;83(2  
1205 Suppl):52-57. doi: 10.4269/ajtmh.2010.09-0291.
- 1206  
1207 20. Riou O, Phillipe B, Jouan A, Coulibaly I, Mondo M, Digoutte JP. Les formes  
1208 neurologiques et neurosensorielles de la fièvre de Valley du Rift en Mauritanie. *Bulletin  
1209 de la Societe de Phologie Exotiques.* 1989;82:605-610.
- 1210

- 1211 21. Kahlon SS, Peters CJ, Leduc J, Muchiri EM, Muiruri S, Njenga MK, et al. Severe  
1212 Rift Valley fever may present with a characteristic clinical syndrome. *Am J Trop Med*  
1213 *Hyg.* 2010;82(3):371-375. doi: 10.4269/ajtmh.2010.09-0669.
- 1214  
1215 22. Kim Y, Metras R, Dommergues L, Youssouffi C, Combo S, Le Godais G, et al. The  
1216 role of livestock movements in the spread of Rift Valley fever virus in animals and  
1217 humans in Mayotte, 2018-19. *PLoS Negl Trop Dis.* 2021;15(3):e0009202. doi:  
1218 10.1371/journal.pntd.0009202.
- 1219  
1220 23. OIE. Rift Valley Fever (RVF): OIE; 2021. Available from:  
1221 <https://www.oie.int/en/animal-health-in-the-world/animal-diseases/rift-valley-fever/>.
- 1222  
1223 24. Davies FG, Linthicum KJ, James AD. Rainfall and epizootic Rift Valley Fever. *Bull*  
1224 *World Health Organ.* 1985;63:941-943.
- 1225  
1226 25. Linthicum KJ, Anyamba A, Tucker CJ, Kelley PW, Myers MF, Peters CJ. Climate  
1227 and satellite indicators to forecast Rift Valley fever epidemics in Kenya. *Science.*  
1228 1999;285:397-400.
- 1229  
1230 26. Linthicum KJ, Bailey CL, Davies FG, Tucker CJ. Detection of Rift Valley fever viral  
1231 activity in Kenya by satellite remote sensing imagery. *Science.* 1987;235(4796):1656-  
1232 1659. Epub 1987/03/27.
- 1233  
1234 27. Linthicum KJ, Bailey CL, Tucker CJ, Mitchell KD, Logan TM, Davies FG, et al.  
1235 Application of polar-orbiting, meteorological satellite data to detect flooding of Rift Valley  
1236 fever virus vector mosquito habitats in Kenya. *Med Vet Entomol.* 1990;4(4):433-438.  
1237 Epub 1990/10/01.
- 1238  
1239 28. Anyamba A, Chretien JP, Formenty PB, Small J, Tucker CJ, Malone JL, et al. Rift  
1240 Valley fever potential, Arabian Peninsula. *Emerg Infect Dis.* 2006;12(3):518-520. Epub  
1241 2006/05/23. doi: 10.3201/eid1203.050973.
- 1242  
1243 29. Anyamba A, Chretien JP, Small J, Tucker CJ, Formenty PB, Richardson JH, et al.  
1244 Prediction of a Rift Valley fever outbreak. *Proc Natl Acad Sci U S A.* 2009;106(3):955-  
1245 959. doi: 10.1073/pnas.0806490106.
- 1246  
1247 30. Anyamba A, Chretien JP, Small J, Tucker CJ, Linthicum KJ. Developing global  
1248 climate anomalies suggest potential disease risks for 2006-2007. *Int J Health Geogr.*  
1249 2006;5:60. Epub 2006/12/30. doi: 10.1186/1476-072x-5-60.

- 1250  
1251 31. Anyamba A, Linthicum KJ, Small J, Britch SC, Pak E, de La Rocque S, et al.  
1252 Prediction, assessment of the Rift Valley fever activity in East and southern Africa 2006-  
1253 2008 and possible vector control strategies. *Am J Trop Med Hyg.* 2010;83(2 Suppl):43-  
1254 51. doi: 10.4269/ajtmh.2010.09-0289.
- 1255  
1256 32. Anyamba A, Linthicum KJ, Tucker CJ. Climate-disease connections: Rift Valley  
1257 fever in Kenya. *Cad Saude Publica.* 2001;17 Suppl:133-140. Epub 2001/06/27. doi:  
1258 10.1590/s0102-311x2001000700022.
- 1259  
1260 33. Ahmed A, Makame J, Robert F, Julius K, Mecky M. Sero-prevalence and spatial  
1261 distribution of Rift Valley fever infection among agro-pastoral and pastoral communities  
1262 during interepidemic period in the Serengeti ecosystem, northern Tanzania. *BMC Infect*  
1263 *Dis.* 2018;18(1):276. Epub 2018/06/15. doi: 10.1186/s12879-018-3183-9.
- 1264  
1265 34. Tigoi C, Sang R, Chepkorir E, Orindi B, Arum SO, Mulwa F, et al. High risk for  
1266 human exposure to Rift Valley fever virus in communities living along livestock  
1267 movement routes: A cross-sectional survey in Kenya. *PLoS Negl Trop Dis.*  
1268 2020;14(2):e0007979. Epub 2020/02/23. doi: 10.1371/journal.pntd.0007979.
- 1269  
1270 35. Sanderson CE, Jori F, Moolla N, Paweska JT, Oumer N, Alexander KA. Silent  
1271 circulation of Rift Valley fever in humans, Botswana, 2013-2014. *Emerg Infect Dis.*  
1272 2020;26(10):2453-2456. Epub 2020/09/19. doi: 10.3201/eid2610.191837.
- 1273  
1274 36. Schoepp RJ, Rossi CA, Khan SH, Goba A, Fair JN. Undiagnosed acute viral febrile  
1275 illnesses, Sierra Leone. *Emerging Infectious Diseases.* 2014;20(7):1176-1182. doi:  
1276 10.3201/eid2007.131265.
- 1277  
1278 37. Bosworth A, Ghabbari T, Dowall S, Varghese A, Fares W, Hewson R, et al.  
1279 Serologic evidence of exposure to Rift Valley fever virus detected in Tunisia. *New*  
1280 *Microbes New Infect.* 2016;9:1-7. doi: 10.1016/j.nmni.2015.10.010.
- 1281  
1282 38. Dellagi K, Salez N, Maquart M, Larrieu S, Yssouf A, Silai R, et al. Serological  
1283 evidence of contrasted exposure to arboviral infections between islands of the Union of  
1284 Comoros (Indian Ocean). *PloS Neglected Tropical Diseases.* 2016;10(12). doi:  
1285 10.1371/journal.pntd.0004840.
- 1286  
1287 39. Durand JP, Bouloy M, Richecoeur L, Peyrefitte CN, Tolou H. Rift Valley fever virus  
1288 infection among French troops in Chad. *Emerg Infect Dis.* 2003;9(6):751-752. Epub  
1289 2003/06/05. doi: 10.3201/eid0906.020647.

- 1290  
1291 40. Guillebaud J, Bernardson B, Randriambolamanantsoa TH, Randrianasolo L,  
1292 Randriamampionona JL, Marino CA, et al. Study on causes of fever in primary  
1293 healthcare center uncovers pathogens of public health concern in Madagascar. PLoS  
1294 Negl Trop Dis. 2018;12(7):e0006642. Epub 2018/07/17. doi:  
1295 10.1371/journal.pntd.0006642.
- 1296  
1297 41. Gudo ES, Pinto G, Weyer J, le Roux C, Mandlaze A, José AF, et al. Serological  
1298 evidence of rift valley fever virus among acute febrile patients in Southern Mozambique  
1299 during and after the 2013 heavy rainfall and flooding: implication for the management of  
1300 febrile illness. Virol J. 2016;13:96. Epub 2016/06/10. doi: 10.1186/s12985-016-0542-2.
- 1301  
1302 42. Sow A, Faye O, Faye O, Diallo D, Sadio BD, Weaver SC, et al. Rift Valley fever in  
1303 Kedougou, southeastern Senegal, 2012. Emerg Infect Dis. 2014;20(3):504-506. Epub  
1304 2014/02/26. doi: 10.3201/eid2003.131174.
- 1305  
1306 43. Sumaye RD, Abatih EN, Thiry E, Amuri M, Berkvens D, Geubbels E. Inter-epidemic  
1307 acquisition of Rift Valley fever virus in humans in Tanzania. PLoS Negl Trop Dis.  
1308 2015;9(2):e0003536. Epub 2015/02/28. doi: 10.1371/journal.pntd.0003536.
- 1309  
1310 44. Liu J, Sun Y, Shi W, Tan S, Pan Y, Cui S, et al. The first imported case of Rift  
1311 Valley fever in China reveals a genetic reassortment of different viral lineages. Emerg  
1312 Microbes Infect. 2017;6(1):e4. Epub 2017/01/18. doi: 10.1038/emi.2016.136.
- 1313  
1314 45. Oltmann A, Kämper S, Staeck O, Schmidt-Chanasit J, Günther S, Berg T, et al.  
1315 Fatal outcome of hepatitis A virus (HAV) infection in a traveler with incomplete HAV  
1316 vaccination and evidence of Rift Valley fever virus infection. J Clin Microbiol.  
1317 2008;46(11):3850-3852. Epub 2008/09/05. doi: 10.1128/jcm.01102-08.
- 1318  
1319 46. Evans A, Gakuya F, Paweska JT, Rostal M, Akoolo L, Van Vuren PJ, et al.  
1320 Prevalence of antibodies against Rift Valley fever virus in Kenyan wildlife. Epidemiology  
1321 and Infection. 2008;136(9):1261-1269. doi: 10.1017/S0950268807009806.
- 1322  
1323 47. LaBeaud AD, Cross PC, Getz WM, Glinka A, King CH. Rift Valley fever virus  
1324 infection in African Buffalo (*Syncerus caffer*) herds in rural South Africa: Evidence of  
1325 interepidemic transmission. American Journal of Tropical Medicine and Hygiene.  
1326 2011;84(4):641-646. doi: 10.4269/ajtmh.2011.10-0187.
- 1327

- 1328 48. Olive MM, Goodman SM, Reynes JM. The role of wild mammals in the  
1329 maintenance of Rift Valley fever virus. *J Wildl Dis.* 2012;48(2):241-266. doi:  
1330 10.7589/0090-3558-48.2.241.
- 1331  
1332 49. Rostal MK, Evans AL, Sang R, Gikundi S, Wakhule L, Munyua P, et al.  
1333 Identification of potential vectors of and detection of antibodies against Rift Valley fever  
1334 virus in livestock during interepizootic periods. *American Journal of Veterinary*  
1335 *Research.* 2010;71(5):522-526. doi: 10.2460/ajvr.71.5.522.
- 1336  
1337 50. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.  
1338 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.  
1339 *Bmj.* 2021;372:n71. doi: 10.1136/bmj.n71.
- 1340  
1341 51. García-Bocanegra I, Paniagua J, Cano-Terriza D, Arenas-Montes A, Fernández-  
1342 Morente M, Napp S. Absence of Rift Valley fever virus in domestic and wild ruminants  
1343 from Spain. *Vet Rec.* 2016;179(2):48. Epub 2016/05/11. doi: 10.1136/vr.103696.
- 1344  
1345 52. Mentaberre G, Gutierrez C, Rodriguez NF, Joseph S, Gonzalez-Barrio D, Cabezon  
1346 O, et al. A transversal study on antibodies against selected pathogens in dromedary  
1347 camels in the Canary Islands, Spain. *Veterinary Microbiology.* 2013;167(3-4):468-473.  
1348 doi: 10.1016/j.vetmic.2013.07.029.
- 1349  
1350 53. Bazanow BA, Stygar D, Romuk E, Skrzep-Poloczek B, Pacon J, Gadzala L, et al.  
1351 Preliminary serological investigation of Rift Valley fever in Poland. *Journal of Vector*  
1352 *Borne Diseases.* 2018;55(4):324-326. doi: 10.4103/0972-9062.256570.
- 1353  
1354 54. Kim HJ, Park JY, Jeoung HY, Yeh JY, Cho YS, Choi JS, et al. Serological  
1355 surveillance studies confirm the Rift Valley fever virus free status in South Korea. *Trop*  
1356 *Anim Health Prod.* 2015;47(7):1427-1430. doi: 10.1007/s11250-015-0858-8.
- 1357  
1358 55. Batieha A, Saliba EK, Graham R, Mohareb E, Hijazi Y, Wijeyaratne P.  
1359 Seroprevalence of West Nile, Rift Valley, and sandfly arboviruses in Hashimiah, Jordan.  
1360 *Emerg Infect Dis.* 2000;6(4):358-362. Epub 2000/07/25. doi: 10.3201/eid0604.000405.
- 1361  
1362 56. Freeman MC, Garn JV, Sclar GD, Boisson S, Medlicott K, Alexander KT, et al. The  
1363 impact of sanitation on infectious disease and nutritional status: A systematic review  
1364 and meta-analysis. *Int J Hyg Environ Health.* 2017;220(6):928-949. doi:  
1365 10.1016/j.ijheh.2017.05.007.
- 1366

- 1367 57. Puzzolo E, Pope D, Stanistreet D, Rehfuess EA, Bruce NG. Clean fuels for  
1368 resource-poor settings: A systematic review of barriers and enablers to adoption and  
1369 sustained use. *Environ Res.* 2016;146:218-234. doi: 10.1016/j.envres.2016.01.002.
- 1370  
1371 58. Hardcastle AN, Osborne JCP, Ramshaw RE, Hullah EN, Morgan JD, Miller-Petrie  
1372 MK, et al. Informing Rift Valley fever preparedness by mapping seasonally varying  
1373 environmental suitability. *Int J Infect Dis.* 2020;99:362-372. Epub 2020/08/02. doi:  
1374 10.1016/j.ijid.2020.07.043.
- 1375  
1376 59. Redding DW, Tiedt S, Lo Iacono G, Bett B, Jones KE. Spatial, seasonal and  
1377 climatic predictive models of Rift Valley fever disease across Africa. *Philos Trans R Soc*  
1378 *Lond B Biol Sci.* 2017;372(1725). Epub 2017/06/07. doi: 10.1098/rstb.2016.0165.
- 1379  
1380 60. Williams R, Malherbe J, Weepener H, Majiwa P, Swanepoel R. Anomalous high  
1381 rainfall and soil saturation as combined risk indicator of Rift Valley fever outbreaks,  
1382 South Africa, 2008-2011. *Emerg Infect Dis.* 2016;22(12):2054-2062. Epub 2016/07/13.  
1383 doi: 10.3201/eid2212.151352.
- 1384  
1385 61. Hightower A, Kinkade C, Nguku PM, Anyangu A, Mutonga D, Omolo J, et al.  
1386 Relationship of climate, geography, and geology to the incidence of Rift Valley fever in  
1387 Kenya during the 2006-2007 outbreak. *American Journal of Tropical Medicine and*  
1388 *Hygiene.* 2012;86(2):373-380. doi: 10.4269/ajtmh.2012.11-0450.
- 1389  
1390 62. Verster AM, Liang JE, Rostal MK, Kemp A, Brand RF, Anyamba A, et al. Selected  
1391 wetland soil properties correlate to Rift Valley fever livestock mortalities reported in  
1392 2009-10 in central South Africa. *PLoS One.* 2020;15(5):e0232481. Epub 2020/05/19.  
1393 doi: 10.1371/journal.pone.0232481.
- 1394  
1395 63. Sindato C, Pfeiffer DU, Karimuribo ED, Mboera LE, Rweyemamu MM, Paweska JT.  
1396 A spatial analysis of Rift Valley fever virus seropositivity in domestic ruminants in  
1397 Tanzania. *PLoS One.* 2015;10(7):e0131873. Epub 2015/07/15. doi:  
1398 10.1371/journal.pone.0131873.
- 1399  
1400 64. Nicholas DE, Jacobsen KH, Waters NM. Risk factors associated with human Rift  
1401 Valley fever infection: systematic review and meta-analysis. *Trop Med Int Health.*  
1402 2014;19(12):1420-1429. doi: 10.1111/tmi.12385.
- 1403  
1404 65. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.*  
1405 2002;21(11):1539-1558. Epub 2002/07/12. doi: 10.1002/sim.1186.
- 1406

- 1407 66. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining  
1408 heterogeneity and combining results from several studies in meta-analysis. In: Egger M,  
1409 Smith GD, Altman DG, editors. *Systematic Reviews in Health Care: Meta-analysis in*  
1410 *Context*. London: BMJ Books; 2001. p. 285-312.
- 1411  
1412 67. Clark MHA, Warimwe GM, Di Nardo A, Lyons NA, Gubbins S. Systematic literature  
1413 review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in  
1414 Africa from 1968 to 2016. *PloS Neglected Tropical Diseases*. 2018;12(7). doi:  
1415 10.1371/journal.pntd.0006627.
- 1416  
1417 68. LaBeaud AD, Muchiri EM, Ndzovu M, Mwanje MT, Muiruri S, Peters CJ, et al.  
1418 Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya. *Emerg Infect*  
1419 *Dis*. 2008;14(8):1240-1246. doi: 10.3201/eid1408.080082.
- 1420  
1421 69. McElroy AK, Albariño CG, Nichol ST. Development of a RVFV ELISA that can  
1422 distinguish infected from vaccinated animals. *Virol J*. 2009;6:125. Epub 2009/08/15. doi:  
1423 10.1186/1743-422x-6-125.
- 1424  
1425 70. Paweska JT, Burt FJ, Swanepoel R. Validation of IgG-sandwich and IgM-capture  
1426 ELISA for the detection of antibody to Rift Valley fever virus in humans. *J Virol Methods*.  
1427 2005;124(1-2):173-181. Epub 2005/01/25. doi: 10.1016/j.jviromet.2004.11.020.
- 1428  
1429 71. Paweska JT, Jansen van Vuren P, Swanepoel R. Validation of an indirect ELISA  
1430 based on a recombinant nucleocapsid protein of Rift Valley fever virus for the detection  
1431 of IgG antibody in humans. *J Virol Methods*. 2007;146(1-2):119-124. Epub 2007/07/25.  
1432 doi: 10.1016/j.jviromet.2007.06.006.
- 1433  
1434 72. Jansen van Vuren P, Paweska JT. Laboratory safe detection of nucleocapsid  
1435 protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA.  
1436 *J Virol Methods*. 2009;157(1):15-24. Epub 2009/01/07. doi:  
1437 10.1016/j.jviromet.2008.12.003.
- 1438  
1439 73. Wichgers Schreur PJ, Paweska JT, Kant J, Kortekaas J. A novel highly sensitive,  
1440 rapid and safe Rift Valley fever virus neutralization test. *J Virol Methods*. 2017;248:26-  
1441 30. doi: 10.1016/j.jviromet.2017.06.001.
- 1442  
1443 74. Sobarzo A, Paweska JT, Herrmann S, Amir T, Marks RS, Lobel L. Optical fiber  
1444 immunosensor for the detection of IgG antibody to Rift Valley fever virus in humans.  
1445 *Journal of Virological Methods*. 2007;146(1-2):327-334. doi:  
1446 10.1016/j.jviromet.2007.07.017.

- 1447  
1448 75. van der Wal FJ, Achterberg RP, de Boer SM, Boshra H, Brun A, Maassen CB, et al.  
1449 Bead-based suspension array for simultaneous detection of antibodies against the Rift  
1450 Valley fever virus nucleocapsid and Gn glycoprotein. *J Virol Methods*. 2012;183(2):99-  
1451 105. doi: 10.1016/j.jviromet.2012.03.008.
- 1452  
1453 76. Petrova V, Kristiansen P, Norheim G, Yimer SA. Rift valley fever: diagnostic  
1454 challenges and investment needs for vaccine development. *BMJ Glob Health*.  
1455 2020;5(8). Epub 2020/08/21. doi: 10.1136/bmjgh-2020-002694.
- 1456  
1457 77. Beechler BR, Manore CA, Reininghaus B, O'Neal D, Gorsich EE, Ezenwa VO, et al.  
1458 Enemies and turncoats: bovine tuberculosis exposes pathogenic potential of Rift Valley  
1459 fever virus in a common host, African buffalo (*Syncerus caffer*). *Proc Biol Sci*.  
1460 2015;282(1805). Epub 2015/03/20. doi: 10.1098/rspb.2014.2942.
- 1461  
1462 78. Capobianco Dondona A, Aschenborn O, Pinoni C, Di Gialleonardo L, Maseke A,  
1463 Bortone G, et al. Rift Valley fever virus among wild ruminants, Etosha National Park,  
1464 Namibia, 2011. *Emerg Infect Dis*. 2016;22(1):128-130. doi: 10.3201/eid2201.150725.
- 1465  
1466 79. Sindato C, Swai ES, Karimuribo ED, Dautu G, Pfeiffer DU, Mboera LEG, et al.  
1467 Spatial distribution of non-clinical Rift Valley fever viral activity in domestic and wild  
1468 ruminants in northern Tanzania. *Tanzania Veterinary Journal*. 2013;28 (Special):21-38.
- 1469  
1470 80. Selmi R, Mamlouk A, Ben Said M, Ben Yahia H, Abdelaali H, Ben Chehida F, et al.  
1471 First serological evidence of the Rift Valley fever Phlebovirus in Tunisian camels. *Acta  
1472 Trop*. 2020;207:105462. Epub 2020/04/24. doi: 10.1016/j.actatropica.2020.105462.
- 1473  
1474 81. Di Nardo A, Rossi D, Saleh SM, Lejlifa SM, Hamdi SJ, Di Gennaro A, et al.  
1475 Evidence of Rift Valley fever seroprevalence in the Sahrawi semi-nomadic pastoralist  
1476 system, Western Sahara. *BMC Vet Res*. 2014;10:92. Epub 2014/04/25. doi:  
1477 10.1186/1746-6148-10-92.
- 1478  
1479 82. Kanouté YB, Gagnon BG, Schindler C, Bonfoh B, Schelling E. Epidemiology of  
1480 brucellosis, Q Fever and Rift Valley fever at the human and livestock interface in  
1481 northern Côte d'Ivoire. *Acta Trop*. 2017;165:66-75. Epub 2016/02/24. doi:  
1482 10.1016/j.actatropica.2016.02.012.
- 1483  
1484 83. Andayi F, Charrel RN, Kieffer A, Richet H, Pastorino B, Leparç-Goffart I, et al. A  
1485 sero-epidemiological study of arboviral fevers in Djibouti, Horn of Africa. *PLoS Negl  
1486 Trop Dis*. 2014;8(12):e3299. Epub 2014/12/17. doi: 10.1371/journal.pntd.0003299.



- 1487  
1488 84. Umuhoza T, Berkvens D, Gafarasi I, Rukelibuga J, Mushonga B, Biryomumaisho S.  
1489 Seroprevalence of Rift Valley fever in cattle along the Akagera-Nyabarongo rivers,  
1490 Rwanda. *J S Afr Vet Assoc.* 2017;88(0):e1-e5. doi: 10.4102/jsava.v88i0.1379.
- 1491  
1492 85. Dutuze MF, Ingabire A, Gafarasi I, Uwituze S, Nzayirambaho M, Christofferson RC.  
1493 Identification of Bunyamwera and possible other Orthobunyavirus infections and  
1494 disease in cattle during a Rift Valley fever outbreak in Rwanda in 2018. *Am J Trop Med*  
1495 *Hyg.* 2020;103(1):183-189. Epub 2020/04/22. doi: 10.4269/ajtmh.19-0596.
- 1496  
1497 86. Bonney JH, Osei-Kwasi M, Adiku TK, Barnor JS, Amesiya R, Kubio C, et al.  
1498 Hospital-based surveillance for viral hemorrhagic fevers and hepatitides in Ghana.  
1499 *PLoS Negl Trop Dis.* 2013;7(9):e2435. Epub 2013/09/27. doi:  
1500 10.1371/journal.pntd.0002435.
- 1501  
1502 87. Bird BH, Githinji JW, Macharia JM, Kasiiti JL, Muriithi RM, Gacheru SG, et al.  
1503 Multiple virus lineages sharing recent common ancestry were associated with a large  
1504 Rift Valley fever outbreak among livestock in Kenya during 2006-2007. *J Virol.*  
1505 2008;82(22):11152-11166. doi: 10.1128/JVI.01519-08.
- 1506  
1507 88. Miller BR, Godsey MS, Crabtree MB, Savage HM, Al-Mazrao Y, Al-Jeffri MH, et al.  
1508 Isolation and genetic characterization of Rift Valley fever virus from *Aedes vexans*  
1509 *arabiensis*, Kingdom of Saudi Arabia. *Emerg Infect Dis.* 2002;8(12):1492-1494. Epub  
1510 2002/12/25. doi: 10.3201/eid0812.020194.
- 1511  
1512 89. Nderitu L, Lee JS, Omolo J, Omulo S, O'Guinn ML, Hightower A, et al. Sequential  
1513 Rift Valley fever outbreaks in eastern Africa caused by multiple lineages of the virus. *J*  
1514 *Infect Dis.* 2011;203(5):655-665. doi: 10.1093/infdis/jiq004.
- 1515  
1516 90. Maquart M, Pascalis H, Abdourohmane S, Roger M, Abdourahime F, Cardinale E,  
1517 et al. Phylogeographic reconstructions of a Rift Valley fever virus strain reveals  
1518 transboundary animal movements from eastern continental Africa to the Union of the  
1519 Comoros. *Transbound Emerg Dis.* 2016;63(2):e281-285. Epub 2014/09/13. doi:  
1520 10.1111/tbed.12267.
- 1521  
1522 91. Ratovonjato J, Olive MM, Tantely LM, Andrianaivolambo L, Tata E, Razainirina J, et  
1523 al. Detection, isolation, and genetic characterization of Rift Valley fever virus from  
1524 *Anopheles (Anopheles) coustani*, *Anopheles (Anopheles) squamosus*, and *Culex*  
1525 (*Culex*) *antennatus* of the Haute Matsiatra region, Madagascar. *Vector Borne Zoonotic*  
1526 *Dis.* 2011;11(6):753-759. Epub 2010/10/30. doi: 10.1089/vbz.2010.0031.

- 1527  
1528 92. Andriamandimby SF, Randrianarivo-Solofoniaina AE, Jeanmaire EM,  
1529 Ravololomanana L, Razafimanantsoa LT, Rakotojoelinandrasana T, et al. Rift Valley  
1530 fever during rainy seasons, Madagascar, 2008 and 2009. *Emerg Infect Dis.*  
1531 2010;16(6):963-970. doi: 10.3201/eid1606.091266.
- 1532  
1533 93. Faye O, Ba H, Ba Y, Freire CC, Faye O, Ndiaye O, et al. Reemergence of Rift  
1534 Valley fever, Mauritania, 2010. *Emerg Infect Dis.* 2014;20(2):300-303. Epub 2014/01/23.  
1535 doi: 10.3201/eid2002.130996.
- 1536  
1537 94. Sow A, Faye O, Ba Y, Diallo D, Fall G, Faye O, et al. Widespread Rift Valley fever  
1538 emergence in Senegal in 2013-2014. *Open Forum Infect Dis.* 2016;3(3):ofw149. Epub  
1539 2016/10/06. doi: 10.1093/ofid/ofw149.
- 1540  
1541 95. Sow A, Faye O, Ba Y, Ba H, Diallo D, Faye O, et al. Rift Valley fever outbreak,  
1542 southern Mauritania, 2012. *Emerg Infect Dis.* 2014;20(2):296-299. Epub 2014/01/23.  
1543 doi: 10.3201/eid2002.131000.
- 1544  
1545 96. Lagare A, Fall G, Ibrahim A, Ousmane S, Sadio B, Abdoulaye M, et al. First  
1546 occurrence of Rift Valley fever outbreak in Niger, 2016. *Vet Med Sci.* 2019;5(1):70-78.  
1547 Epub 2018/11/10. doi: 10.1002/vms3.135.
- 1548  
1549 97. Grobbelaar AA, Weyer J, Leman PA, Kemp A, Paweska JT, Swanepoel R.  
1550 Molecular epidemiology of Rift Valley fever virus. *Emerg Infect Dis.* 2011;17(12):2270-  
1551 2276. Epub 2011/12/17. doi: 10.3201/eid1712.111035.
- 1552  
1553 98. van Schalkwyk A, Gwala S, Schuck KN, Quan M, Davis AS, Romito M, et al.  
1554 Retrospective phylogenetic analyses of formalin-fixed paraffin-embedded samples from  
1555 the 2011 Rift Valley fever outbreak in South Africa, through sequencing of targeted  
1556 regions. *J Virol Methods.* 2020;287:114003. Epub 2020/11/10. doi:  
1557 10.1016/j.jviromet.2020.114003.
- 1558  
1559 99. van Schalkwyk A, Romito M. Genomic characterization of Rift Valley fever virus,  
1560 South Africa, 2018. *Emerg Infect Dis.* 2019;25(10):1979-1981. Epub 2019/09/21. doi:  
1561 10.3201/eid2510.181748.
- 1562  
1563 100. Liu W, Sun FJ, Tong YG, Zhang SQ, Cao WC. Rift Valley fever virus imported into  
1564 China from Angola. *Lancet Infect Dis.* 2016;16(11):1226. Epub 2016/10/30. doi:  
1565 10.1016/s1473-3099(16)30401-7.
- 1566

- 1567 101. Grobbelaar AA, Weyer J, Leman P, Kemp A, Paweska JT. Phylogeny of Rift Valley  
1568 fever virus isolates recovered from humans during 2008-2011 disease outbreaks in  
1569 South Africa. *International Journal of Infectious Diseases*. 2014;21:224-224. doi:  
1570 10.1016/j.ijid.2014.03.887.
- 1571  
1572 102. Bett B, Said MY, Sang R, Bukachi S, Wanyoike S, Kifugo SC, et al. Effects of flood  
1573 irrigation on the risk of selected zoonotic pathogens in an arid and semi-arid area in the  
1574 eastern Kenya. *PLoS One*. 2017;12(5). doi: 10.1371/journal.pone.0172626.
- 1575  
1576 103. LaBeaud AD, Muiruri S, Sutherland LJ, Dahir S, Gildengorin G, Morrill J, et al.  
1577 Postepidemic analysis of Rift Valley fever virus transmission in northeastern Kenya: a  
1578 village cohort study. *PLoS Negl Trop Dis*. 2011;5(8):e1265. doi:  
1579 10.1371/journal.pntd.0001265.
- 1580  
1581 104. Arishi H, Ageel A, Rahman MA, Al Hazmi A, Arishi AR, Ayoola B, et al. Update:  
1582 Outbreak of Rift Valley fever - Saudi Arabia, August-November 2000 (Reprinted from  
1583 *MMWR*, vol 49, pg 982-986, 2000). *Journal of the American Medical Association*.  
1584 2000;284(23):2989-2990.
- 1585  
1586 105. Rift Valley fever, Saudi Arabia, August-October 2000. *Wkly Epidemiol Rec*.  
1587 2000;75(46):370-371. Epub 2001/01/06.
- 1588  
1589 106. Outbreak of Rift Valley fever, Yemen, August-October 2000. *Wkly Epidemiol Rec*.  
1590 2000;75(48):392-395. Epub 2001/01/06.
- 1591  
1592 107. Hanafi HA, Fryauff DJ, Saad MD, Soliman AK, Mohareb EW, Medhat I, et al. Virus  
1593 isolations and high population density implicate *Culex antennatus* (Becker) (Diptera:  
1594 Culicidae) as a vector of Rift Valley fever virus during an outbreak in the Nile Delta of  
1595 Egypt. *Acta Trop*. 2011;119(2-3):119-124. Epub 2011/05/17. doi:  
1596 10.1016/j.actatropica.2011.04.018.
- 1597  
1598 108. Faye O, Diallo M, Diop D, Bezeid OE, Bâ H, Niang M, et al. Rift Valley fever  
1599 outbreak with East-Central African virus lineage in Mauritania, 2003. *Emerg Infect Dis*.  
1600 2007;13(7):1016-1023. Epub 2008/01/25. doi: 10.3201/eid1307.061487.
- 1601  
1602 109. Sindato C, Karimuribo ED, Pfeiffer DU, Mboera LE, Kivaria F, Dautu G, et al.  
1603 Spatial and temporal pattern of Rift Valley fever outbreaks in Tanzania; 1930 to 2007.  
1604 *PLoS One*. 2014;9(2):e88897. Epub 2014/03/04. doi: 10.1371/journal.pone.0088897.
- 1605

- 1606 110. El Mamy AB, Baba MO, Barry Y, Isselmou K, Dia ML, El Kory MO, et al.  
1607 Unexpected Rift Valley fever outbreak, northern Mauritania. *Emerg Infect Dis.*  
1608 2011;17(10):1894-1896. Epub 2011/10/18. doi: 10.3201/eid1710.110397.
- 1609  
1610 111. El Mamy AB, Kane Y, El Arbi AS, Barry Y, Bernard C, Lancelot R, et al. L'épidémie  
1611 de la fièvre de la Vallée du Rift en 2012 en Mauritanie. *Revue Africaine de Santé et*  
1612 *Productions Animales.* 2014;12(3-4):169-173.
- 1613  
1614 112. Shoemaker T, Balinandi S, Nyakarahuka L, Ojwang J, Tumusiime A, Mulei S, et al.  
1615 First laboratory confirmation of an outbreak of Rift Valley fever virus in 50 Years in  
1616 Kabale District, southwestern Uganda. *American Journal of Tropical Medicine and*  
1617 *Hygiene.* 2017;95(5):437-437.
- 1618  
1619 113. Hassan A, Muturi M, Mwatondo A, Omolo J, Bett B, Gikundi S, et al.  
1620 Epidemiological investigation of a Rift Valley fever outbreak in humans and livestock in  
1621 Kenya, 2018. *Am J Trop Med Hyg.* 2020;103(4):1649-1655. Epub 2020/08/05. doi:  
1622 10.4269/ajtmh.20-0387.
- 1623  
1624 114. Youssouf H, Subiros M, Denetiere G, Collet L, Dommergues L, Pauvert A, et al.  
1625 Rift Valley fever outbreak, Mayotte, France, 2018-2019. *Emerg Infect Dis.*  
1626 2020;26(4):769-772. Epub 2020/03/19. doi: 10.3201/eid2604.191147.
- 1627  
1628 115. van Vuren PJ, Kgaladi J, Patharoo V, Ohaebosim P, Msimang V, Nyokong B, et al.  
1629 Human cases of Rift Valley fever in South Africa, 2018. *Vector-Borne and Zoonotic*  
1630 *Diseases.* 2018;18(12):713-715. doi: 10.1089/vbz.2018.2357.
- 1631  
1632 116. Youssef HM, Ghoneim MA, al. e. Recent trends for diagnosis of Rift Valley  
1633 fever in animals and mosquitoes in Egypt with special reference to the carrier.  
1634 *Global Veterinaria.* 2008;2(1).
- 1635  
1636 117. Jeffries CL, Tantely LM, Raharimalala FN, Hurn E, Boyer S, Walker T. Diverse  
1637 novel resident *Wolbachia* strains in Culicine mosquitoes from Madagascar. *Scientific*  
1638 *Reports.* 2018;8. doi: 10.1038/s41598-018-35658-z.
- 1639  
1640 118. Ndiaye EH, Diallo D, Fall G, Ba Y, Faye O, Dia I, et al. Arboviruses isolated from  
1641 the Barkedji mosquito-based surveillance system, 2012-2013. *BMC Infect Dis.*  
1642 2018;18(1):642. Epub 2018/12/14. doi: 10.1186/s12879-018-3538-2.
- 1643

- 1644 119. Abdelgadir DM, Bashab HMM, Mohamed RAE, Abuelmaali SA. Risk factor  
1645 analysis for outbreak of Rift Valley fever in Khartoum State of Sudan. Journal of  
1646 Entomological Science. 2010;45(3):239-251. doi: 10.18474/0749-8004-45.3.239.
- 1647  
1648 120. Mbanzulu KM, Mboera LEG, Luzolo FK, Wumba R, Misinzo G, Kimera SI.  
1649 Mosquito-borne viral diseases in the Democratic Republic of the Congo: a review.  
1650 Parasit Vectors. 2020;13(1):103. Epub 2020/02/28. doi: 10.1186/s13071-020-3985-7.
- 1651  
1652 121. Mohamed RAE, Mohamed N, Aleanizy FS, Alqahtani FY, Al Khalaf A, Al-Keridis  
1653 LA. Investigation of hemorrhagic fever viruses inside wild populations of ticks: One of  
1654 the pioneer studies in Saudi Arabia. Asian Pacific Journal of Tropical Disease.  
1655 2017;7:299-303.
- 1656  
1657 122. Mohamed M, Mosha F, Mghamba J, Zaki SR, Shieh WJ, Paweska J, et al.  
1658 Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in  
1659 Tanzania, 2007. Am J Trop Med Hyg. 2010;83(2 Suppl):22-27. doi:  
1660 10.4269/ajtmh.2010.09-0318.
- 1661  
1662 123. LaBeaud AD, Pfeil S, Muiruri S, Dahir S, Sutherland LJ, Traylor Z, et al. Factors  
1663 associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya.  
1664 PLoS Negl Trop Dis. 2015;9(3):e0003548. Epub 2015/03/13. doi:  
1665 10.1371/journal.pntd.0003548.
- 1666  
1667 124. Anyangu AS, Gould LH, Sharif SK, Nguku PM, Omolo JO, Mutonga D, et al. Risk  
1668 factors for severe Rift Valley fever infection in Kenya, 2007. Am J Trop Med Hyg.  
1669 2010;83(2 Suppl):14-21. doi: 10.4269/ajtmh.2010.09-0293.
- 1670  
1671 125. Seufi AM, Galal FH. Role of *Culex* and *Anopheles* mosquito species as potential  
1672 vectors of Rift Valley fever virus in Sudan outbreak, 2007. BMC Infect Dis. 2010;10:65.  
1673 Epub 2010/03/13. doi: 10.1186/1471-2334-10-65.
- 1674  
1675 126. Oyas H, Holmstrom L, Kemunto NP, Muturi M, Mwatondo A, Osoro E, et al.  
1676 Enhanced surveillance for Rift Valley fever in livestock during El Niño rains and threat of  
1677 RVF outbreak, Kenya, 2015-2016. PLoS Negl Trop Dis. 2018;12(4):e0006353. Epub  
1678 2018/04/27. doi: 10.1371/journal.pntd.0006353.
- 1679  
1680 127. Bashir RSE, Hassan OA. A One Health perspective to identify environmental  
1681 factors that affect Rift Valley fever transmission in Gezira state, Central Sudan. Tropical  
1682 Medicine and Health. 2019;47(1). doi: 10.1186/s41182-019-0178-1.
- 1683

- 1684 128. van Vuren PJ, Shalekoff S, Grobbelaar AA, Archer BN, Thomas J, Tiemessen CT,  
1685 et al. Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative  
1686 of severe disease. *Virology Journal*. 2015;12. doi: 10.1186/s12985-015-0392-3.
- 1687
- 1688 129. Outbreak news. Rift Valley fever, Kenya. *Wkly Epidemiol Rec*. 2007;82(3):17-18.  
1689 Epub 2007/01/24.
- 1690
- 1691 130. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani  
1692 AM, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and  
1693 laboratory characteristics. *Clin Infect Dis*. 2003;37(8):1084-1092. doi: 10.1086/378747.
- 1694
- 1695 131. Njenga MK, Paweska J, Wanjala R, Rao CY, Weiner M, Omballa V, et al. Using a  
1696 field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever  
1697 cases. *J Clin Microbiol*. 2009;47(4):1166-1171. Epub 2009/01/28. doi:  
1698 10.1128/jcm.01905-08.
- 1699
- 1700 132. Bett B, Lindahl J, Sang R, Wainaina M, Kairu-Wanyoike S, Bukachi S, et al.  
1701 Association between Rift Valley fever virus seroprevalences in livestock and humans  
1702 and their respective intra-cluster correlation coefficients, Tana River County, Kenya.  
1703 *Epidemiology and Infection*. 2019;147. doi: 10.1017/S0950268818003242.
- 1704
- 1705 133. Nicolas G, Chevalier V, Tantely LM, Fontenille D, Durand B. A spatially explicit  
1706 metapopulation model and cattle trade analysis suggests key determinants for the  
1707 recurrent circulation of Rift Valley fever virus in a pilot area of Madagascar highlands.  
1708 *PLoS Negl Trop Dis*. 2014;8(12):e3346. doi: 10.1371/journal.pntd.0003346.
- 1709
- 1710 134. Metras R, Cavalerie L, Dommergues L, Merot P, Edmunds WJ, Keeling MJ, et al.  
1711 The epidemiology of Rift Valley fever in Mayotte: insights and perspectives from 11  
1712 years of data. *PLoS Neglected Tropical Diseases*. 2016;10(6). doi:  
1713 10.1371/journal.pntd.0004783.
- 1714
- 1715 135. Alhaj M. Surveillance study on Rift Valley fever in Jazan region, Saudi Arabia. *Int J*  
1716 *Adv Sci Tech Res*. 2015;5(4):1-13.
- 1717
- 1718 136. Ngoshe YB, Avenant A, Rostal MK, Karesh WB, Paweska JT, Bagge W, et al.  
1719 Patterns of Rift Valley fever virus seropositivity in domestic ruminants in central South  
1720 Africa four years after a large outbreak. *Scientific Reports*. 2020;10(1). doi:  
1721 10.1038/s41598-020-62453-6.
- 1722

- 1723 137. Moiane B, Mapaco L, Thompson P, Berg M, Albihn A, Fafetine J. High  
1724 seroprevalence of Rift Valley fever phlebovirus in domestic ruminants and African  
1725 Buffaloes in Mozambique shows need for intensified surveillance. *Infect Ecol Epidemiol.*  
1726 2017;7(1):1416248. Epub 2018/01/13. doi: 10.1080/20008686.2017.1416248.
- 1727  
1728 138. Caron A, Cornelis D, Foggin C, Hofmeyr M, de Garine-Wichatitsky M. African  
1729 Buffalo movement and zoonotic disease risk across transfrontier conservation areas,  
1730 Southern Africa. *Emerg Infect Dis.* 2016;22(2):277-280. Epub 2016/01/27. doi:  
1731 10.3201/eid2202.140864.
- 1732  
1733 139. Byomi AM, Samaha HA, Zidan SA, Hadad GA. Some associated risk factors with  
1734 the occurrence of Rift Valley fever in animals and man in certain localities of Nile delta,  
1735 Egypt. *Assiut Veterinary Medical Journal.* 2015;61:10-17.
- 1736  
1737 140. Mohamed AM, Ashshi AM, Asghar AH, Abd El-Rahim IH, El-Shemi AG, Zafar T.  
1738 Seroepidemiological survey on Rift Valley fever among small ruminants and their close  
1739 human contacts in Makkah, Saudi Arabia, in 2011. *Rev Sci Tech.* 2014;33(3):903-915.  
1740 doi: 10.20506/rst.33.3.2328.
- 1741  
1742 141. Wensman JJ, Lindahl J, Wachtmeister N, Torsson E, Gwakisa P, Kasanga C, et  
1743 al. A study of Rift Valley fever virus in Morogoro and Arusha regions of Tanzania -  
1744 serology and farmers' perceptions. *Infect Ecol Epidemiol.* 2015;5:30025. doi:  
1745 10.3402/iee.v5.30025.
- 1746  
1747 142. Elfadil AA, Hasab-Allah KA, Dafa-Allah OM. Factors associated with Rift Valley  
1748 fever in south-west Saudi Arabia. *Rev Sci Tech.* 2006;25(3):1137-1145.
- 1749  
1750 143. Mdlulwa Z, Ngwane CB. Evaluating the impact of 2010 Rift Valley fever outbreaks  
1751 on sheep numbers in three provinces of South Africa. *African Journal of Agricultural*  
1752 *Research.* 2017;12(11):979-986.
- 1753  
1754 144. Mroz C, Gwida M, El-Ashker M, Ziegler U, Homeier-Bachmann T, Eiden M, et al.  
1755 Rift Valley fever virus infections in Egyptian cattle and their prevention. *Transbound*  
1756 *Emerg Dis.* 2017;64(6):2049-2058. Epub 2017/01/25. doi: 10.1111/tbed.12616.
- 1757  
1758 145. Abbas B, Yousif MA, M. NH. Animal health constraints to livestock exports from  
1759 the Horn of Africa. *Rev Sci Tech.* 2014;33(3): 711-721.
- 1760

- 1761 146. Mohamed AM, Ghazi H, Ashshi AM, Faidah HS, Clinical EIA. Serological survey of  
1762 Rift Valley fever among sacrifice animals in holy Mecca during pilgrimage season. . Int J  
1763 Trop Med. 2011;6(4):85–89.
- 1764  
1765 147. Tong C, Javelle E, Grard G, Dia A, Lacrosse C, Fourié T, et al. Tracking Rift Valley  
1766 fever: From Mali to Europe and other countries, 2016. Euro Surveill. 2019;24(8). Epub  
1767 2019/02/28. doi: 10.2807/1560-7917.es.2019.24.8.1800213.
- 1768  
1769 148. Liu B, Ma J, Jiao Z, Gao X, Xiao J, Wang H. Risk assessment for the Rift Valley  
1770 fever occurrence in China: Special concern in south-west border areas. Transbound  
1771 Emerg Dis. 2020. Epub 2020/06/23. doi: 10.1111/tbed.13695.
- 1772  
1773 149. Grossi-Soyster EN, LaBeaud AD. Rift Valley fever: Important considerations for  
1774 risk mitigation and future outbreaks. Trop Med Infect Dis. 2020;5(2). doi:  
1775 10.3390/tropicalmed5020089.
- 1776  
1777 150. O'Hearn AE, Voorhees MA, Fetterer DP, Wauquier N, Coomber MR, Bangura J, et  
1778 al. Serosurveillance of viral pathogens circulating in West Africa. Virol J.  
1779 2016;13(1):163. Epub 2016/10/08. doi: 10.1186/s12985-016-0621-4.
- 1780  
1781 151. LaBeaud AD, Ochiai Y, Peters CJ, Muchiri EM, King CH. Spectrum of Rift Valley  
1782 fever virus transmission in Kenya: Insights from three distinct regions. American Journal  
1783 of Tropical Medicine and Hygiene. 2007;76(5):795-800. doi:  
1784 10.4269/ajtmh.2007.76.795.
- 1785  
1786 152. Grossi-Soyster EN, Banda T, Teng CY, Muchiri EM, Mungai PL, Mutuku FM, et al.  
1787 Rift Valley fever seroprevalence in coastal Kenya. Am J Trop Med Hyg. 2017;97(1):115-  
1788 120. Epub 2017/07/19. doi: 10.4269/ajtmh.17-0104.
- 1789  
1790 153. Cook EAJ, Grossi-Soyster EN, de Glanville WA, Thomas LF, Kariuki S, Bronsvort  
1791 BMD, et al. The sero-epidemiology of Rift Valley fever in people in the Lake Victoria  
1792 Basin of western Kenya. Plos Neglected Tropical Diseases. 2017;11(7). doi:  
1793 10.1371/journal.pntd.0005731.
- 1794  
1795 154. Gray GC, Anderson BD, LaBeaud AD, Heraud JM, Fevre EM, Andriamandimby  
1796 SF, et al. Seroepidemiological study of interepidemic Rift Valley fever virus infection  
1797 among persons with intense ruminant exposure in Madagascar and Kenya. Am J Trop  
1798 Med Hyg. 2015;93(6):1364-1370. doi: 10.4269/ajtmh.15-0383.
- 1799



- 1800 155. LaBeaud AD, Bashir F, King CH. Measuring the burden of arboviral diseases: the  
1801 spectrum of morbidity and mortality from four prevalent infections. *Population Health*  
1802 *Metrics*. 2011;9. doi: 10.1186/1478-7954-9-1.
- 1803  
1804 156. Muiruri S, Kabiru EW, Muchiri EM, Hussein H, Kagonda F, LaBeaud AD, et al.  
1805 Cross-sectional survey of Rift Valley fever virus exposure in Bodhei village located in a  
1806 transitional coastal forest habitat in Lamu County, Kenya. *Am J Trop Med Hyg*.  
1807 2015;92(2):394-400. Epub 2014/12/24. doi: 10.4269/ajtmh.14-0440.
- 1808  
1809 157. Nanyingi MO, Munyua P, Kiama SG, Muchemi GM, Thumbi SM, Bitek AO, et al. A  
1810 systematic review of Rift Valley fever epidemiology 1931-2014. *Infect Ecol Epidemiol*.  
1811 2015;5:28024. Epub 2015/08/04. doi: 10.3402/iee.v5.28024.
- 1812  
1813 158. Jori F, Godfroid J, Michel AL, Potts AD, Jaumally MR, Sauzier J, et al. An  
1814 assessment of zoonotic and production limiting pathogens in rusa deer (*Cervus*  
1815 *timorensis rusa*) from Mauritius. *Transbound Emerg Dis*. 2014;61 Suppl 1:31-42. doi:  
1816 10.1111/tbed.12206.
- 1817  
1818 159. Elfving K, Shakely D, Andersson M, Baltzell K, Ali AS, Bachelard M, et al. Acute  
1819 uncomplicated febrile illness in children aged 2-59 months in Zanzibar - aetiologies,  
1820 antibiotic treatment and outcome. *PLoS One*. 2016;11(1):e0146054. Epub 2016/01/29.  
1821 doi: 10.1371/journal.pone.0146054.
- 1822  
1823 160. Nicolas G, Durand B, Duboz R, Rakotondravao R, Chevalier V. Description and  
1824 analysis of the cattle trade network in the Madagascar highlands: potential role in the  
1825 diffusion of Rift Valley fever virus. *Acta Trop*. 2013;126(1):19-27. doi:  
1826 10.1016/j.actatropica.2012.12.013.
- 1827  
1828 161. Abdo-Salem S, Tran A, Grosbois V, Gerbier G, Al-Qadasi M, Saeed K, et al. Can  
1829 environmental and socioeconomic factors explain the recent emergence of Rift Valley  
1830 fever in Yemen, 2000-2001? *Vector Borne Zoonotic Dis*. 2011;11(6):773-779. Epub  
1831 2011/02/03. doi: 10.1089/vbz.2010.0084.
- 1832  
1833 162. Xiao Y, Beier JC, Cantrell RS, Cosner C, DeAngelis DL, Ruan S. Modelling the  
1834 effects of seasonality and socioeconomic impact on the transmission of Rift Valley fever  
1835 virus. *PLoS Negl Trop Dis*. 2015;9(1):e33388. Epub 2015/01/09. doi:  
1836 10.1371/journal.pntd.0003388.
- 1837

- 1838 163. Apolloni A, Nicolas G, Coste C, El Mamy AB, Yahya B, El Arbi AS, et al. Towards  
1839 the description of livestock mobility in Sahelian Africa: Some results from a survey in  
1840 Mauritania. PLoS One. 2018;13(1). doi: 10.1371/journal.pone.0191565.
- 1841  
1842 164. Bergren NA, Borland EM, Hartman DA, Kading RC. Laboratory demonstration of  
1843 the vertical transmission of Rift Valley fever virus by *Culex tarsalis* mosquitoes. PLoS  
1844 Negl Trop Dis. 2021;15(3):e0009273. doi: 10.1371/journal.pntd.0009273.
- 1845  
1846 165. Antonis AF, Kortekaas J, Kant J, Vloet RP, Vogel-Brink A, Stockhofe N, et al.  
1847 Vertical transmission of Rift Valley fever virus without detectable maternal viremia.  
1848 Vector Borne Zoonotic Dis. 2013;13(8):601-606. doi: 10.1089/vbz.2012.1160.
- 1849  
1850 166. Adam I, Karsany MS. Case report: Rift Valley fever with vertical transmission in a  
1851 pregnant Sudanese woman. J Med Virol. 2008;80(5):929. Epub 2008/03/25. doi:  
1852 10.1002/jmv.21132.
- 1853  
1854 167. Arishi HM, Aqeel AY, Al Hazmi MM. Vertical transmission of fatal Rift Valley fever  
1855 in a newborn. Ann Trop Paediatr. 2006;26(3):251-253. doi:  
1856 10.1179/146532806X120363.
- 1857  
1858 168. Baudin M, Jumaa AM, Jomma HJE, Karsany MS, Bucht G, Näslund J, et al.  
1859 Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a  
1860 cross-sectional study. Lancet Glob Health. 2016;4(11):e864-e871. Epub 2016/10/22.  
1861 doi: 10.1016/s2214-109x(16)30176-0.
- 1862  
1863 169. Pienaar NJ, Thompson PN. Temporal and spatial history of Rift Valley fever in  
1864 South Africa: 1950 to 2011. Onderstepoort J Vet Res. 2013;80(1):384. Epub  
1865 2013/05/31. doi: 10.4102/ojvr.v80i1.384.
- 1866  
1867 170. Ndengu M, Matope G, Tivapasi M, Pfukenyi DM, Cetre-Sossah C, De Garine-  
1868 Wichtatsky M. Seroprevalence and associated risk factors of Rift Valley fever in cattle  
1869 and selected wildlife species at the livestock/wildlife interface areas of Gonarezhou  
1870 National Park, Zimbabwe. Onderstepoort J Vet Res. 2020;87(1):e1-e7. Epub  
1871 2020/05/07. doi: 10.4102/ojvr.v87i1.1731.
- 1872  
1873 171. Nyakarahuka L, de St Maurice A, Purpura L, Ervin E, Balinandi S, Tumusiime A, et  
1874 al. Prevalence and risk factors of Rift Valley fever in humans and animals from Kabale  
1875 district in Southwestern Uganda, 2016. PLoS Negl Trop Dis. 2018;12(5):e0006412.  
1876 Epub 2018/05/04. doi: 10.1371/journal.pntd.0006412.
- 1877

- 1878 172. FAO. Rift Valley fever vaccine development, progress and constraints.  
1879 Proceedings of the GF-TADs meeting, January 2011. Rome, Italy: 2011.
- 1880  
1881 173. Bird BH, Nichol ST. Breaking the chain: Rift Valley fever virus control via livestock  
1882 vaccination. *Curr Opin Virol.* 2012;2(3):315-323. Epub 2012/04/03. doi:  
1883 10.1016/j.coviro.2012.02.017.
- 1884  
1885 174. Shoemaker TR, Nyakarahuka L, Balinandi S, Ojwang J, Tumusiime A, Mulei S, et  
1886 al. First laboratory-confirmed outbreak of human and animal Rift Valley fever virus in  
1887 Uganda in 48 years. *Am J Trop Med Hyg.* 2019;100(3):659-671. Epub 2019/01/25. doi:  
1888 10.4269/ajtmh.18-0732.
- 1889  
1890 175. Archer BN, Weyer J, Paweska J, Nkosi D, Leman P, Tint KS, et al. Outbreak of  
1891 Rift Valley fever affecting veterinarians and farmers in South Africa, 2008. *S Afr Med J.*  
1892 2011;101(4):263-266. Epub 2011/07/27. doi: 10.7196/samj.4544.
- 1893  
1894 176. Tambo E, Olalubi OA, Sacko M. Rift Valley fever epidemic in Niger near border  
1895 with Mali. *Lancet Infectious Diseases.* 2016;16(12):1319-1320. doi: 10.1016/S1473-  
1896 3099(16)30477-7.
- 1897  
1898 177. Davies FG. Risk of a Rift Valley fever epidemic at the Hajj in Mecca, Saudi Arabia.  
1899 *Rev Sci Tech.* 2006;25(1):137-147. doi: 10.20506/rst.25.1.1648.
- 1900  
1901 178. Krystosik A, Njoroge G, Odhiambo L, Forsyth JE, Mutuku F, LaBeaud AD. Solid  
1902 wastes provide breeding sites, burrows, and food for biological disease vectors, and  
1903 urban zoonotic reservoirs: A call to action for solutions-based research. *Front Public*  
1904 *Health.* 2019;7:405. doi: 10.3389/fpubh.2019.00405.
- 1905  
1906 179. Salmon-Rousseau A, Piednoir E, Cattoir V, de La Blanchardiere A. Hajj-associated  
1907 infections. *Medecine et Maladies Infectieuses.* 2016.
- 1908  
1909 180. Cecilia H, Métras R, Fall AG, Lo MM, Lancelot R, Ezanno P. It's risky to wander in  
1910 September: Modelling the epidemic potential of Rift Valley fever in a Sahelian setting.  
1911 *Epidemics.* 2020;33:100409. Epub 2020/11/03. doi: 10.1016/j.epidem.2020.100409.
- 1912  
1913 181. Obiero JPO, Onyando JO. Climate. Chapter 5 *in* Developments in Earth Surface  
1914 Processes. 16 2013. p. 39-50.
- 1915

- 1916 182. Alhaji NB, Aminu J, Lawan MK, Babalobi OO, Ghali-Mohammed I, Odetokun IA.  
1917 Seropositivity and associated intrinsic and extrinsic factors for Rift Valley fever virus  
1918 occurrence in pastoral herds of Nigeria: a cross sectional survey. BMC Vet Res.  
1919 2020;16(1):243. Epub 2020/07/16. doi: 10.1186/s12917-020-02455-8.
- 1920  
1921 183. Durand B, Lo Modou M, Tran A, Ba A, Sow F, Belkhiria J, et al. Rift Valley fever in  
1922 northern Senegal: A modelling approach to analyse the processes underlying virus  
1923 circulation recurrence. Plos Neglected Tropical Diseases. 2020;14(6). doi:  
1924 10.1371/journal.pntd.0008009.
- 1925  
1926 184. Kakani S, LaBeaud AD, King CH. Planning for Rift Valley fever virus: use of  
1927 geographical information systems to estimate the human health threat of white-tailed  
1928 deer (*Odocoileus virginianus*)-related transmission. Geospat Health. 2010;5(1):33-43.  
1929 doi: 10.4081/gh.2010.185.
- 1930  
1931 185. Wilson WC, Kim IJ, Trujillo JD, Sunwoo SY, Noronha LE, Urbaniak K, et al.  
1932 Susceptibility of white-tailed deer to Rift Valley fever virus. Emerg Infect Dis.  
1933 2018;24(9):1717-1719. Epub 2018/08/21. doi: 10.3201/eid2409.180265.
- 1934  
1935 186. Bron GM, Strimbu K, Cecilia H, Lerch A, Moore SM, Tran Q, et al. Over 100 Years  
1936 of Rift Valley fever: A patchwork of data on pathogen spread and spillover. Pathogens.  
1937 2021;10(6). doi: 10.3390/pathogens10060708.
- 1938  
1939 187. Schwarz NG, Girmann M, Randriamampionona N, Bialonski A, Maus D, Krefis AC,  
1940 et al. Seroprevalence of antibodies against chikungunya, dengue, and Rift Valley fever  
1941 viruses after febrile illness outbreak, Madagascar. Emerg Infect Dis. 2012;18(11):1780-  
1942 1786. doi: 10.3201/eid1811.111036.
- 1943  
1944 188. Al-Qabati AG, Al-Afaleq AI. Cross-sectional, longitudinal and prospective  
1945 epidemiological studies of Rift Valley fever in Al-Hasa Oasis, Saudi Arabia. Journal of  
1946 Animal and Veterinary Advances. 2010;9(2):258-265.
- 1947  
1948 189. Grossi-Soyster EN, Lee J, King CH, LaBeaud AD. The influence of raw milk  
1949 exposures on Rift Valley fever virus transmission. PLoS Negl Trop Dis.  
1950 2019;13(3):e0007258. doi: 10.1371/journal.pntd.0007258.
- 1951  
1952 190. Cook EAJ, de Glanville WA, Thomas LF, Kariuki S, Bronsvort B, Fevre EM.  
1953 Working conditions and public health risks in slaughterhouses in western Kenya. BMC  
1954 Public Health. 2017;17. doi: 10.1186/s12889-016-3923-y.
- 1955

- 1956 191. Ikegami T, Balogh A, Nishiyama S, Lokugamage N, Saito TB, Morrill JC, et al.  
1957 Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages  
1958 in a mouse model. PLoS One. 2017;12(12):e0189250. Epub 2017/12/22. doi:  
1959 10.1371/journal.pone.0189250.
- 1960  
1961 192. WHO. Factors that contributed to undetected spread of the Ebola virus and  
1962 impeded rapid containment. Geneva, Switzerland: World Health Organization; 2015  
1963 [cited 2021 9/7/2021].
- 1964  
1965 193. de St Maurice A, Nyakarahuka L, Purpura L, Ervin E, Tumusiime A, Balinandi S, et  
1966 al. Notes from the field: Rift Valley fever response - Kabale District, Uganda, March  
1967 2016. MMWR Morb Mortal Wkly Rep. 2016;65(43):1200-1201. Epub 2016/11/05. doi:  
1968 10.15585/mmwr.mm6543a5.
- 1969  
1970 194. Hartley DM, Rinderknecht JL, Nipp TL, Clarke NP, Snowden GD, National Center  
1971 for Foreign Animal Zoonotic Disease Defense Advisory Group on Rift Valley Fever.  
1972 Potential effects of Rift Valley fever in the United States. Emerg Infect Dis.  
1973 2011;17(8):e1. doi: 10.3201/eid1708.101088.
- 1974  
1975 195. Brugere-Picoux J, Chomel B. Importation of tropical diseases to Europe via  
1976 animals and animal products: risks and pathways. Bulletin de L Academie Nationale de  
1977 Medecine. 2009;193(8):1805-1819. doi: 10.1016/S0001-4079(19)32415-X.
- 1978  
1979 196. Cito F, Narcisi V, Danzetta ML, Iannetti S, Sabatino DD, Bruno R, et al. Analysis of  
1980 surveillance systems in place in European Mediterranean countries for West Nile virus  
1981 (WNV) and Rift Valley fever (RVF). Transbound Emerg Dis. 2013;60 Suppl 2:40-44.  
1982 Epub 2014/03/05. doi: 10.1111/tbed.12124.
- 1983  
1984 197. Nielsen SS, Alvarez J, Bicout DJ, Calistri P, Depner K, Drewe JA, et al. Rift Valley  
1985 fever - epidemiological update and risk of introduction into Europe. EFSAJ.  
1986 2020;18(3):e06041. Epub 2020/10/07. doi: 10.2903/j.efsa.2020.6041.
- 1987  
1988 198. Rolin AI, Berrang-Ford L, Kulkarni MA. The risk of Rift Valley fever virus  
1989 introduction and establishment in the United States and European Union. Emerg  
1990 Microbes Infect. 2013;2(12):e81. Epub 2013/12/01. doi: 10.1038/emi.2013.81.
- 1991  
1992 199. Zeller H, Marrama L, Sudre B, Van Bortel W, Warns-Petit E. Mosquito-borne  
1993 disease surveillance by the European Centre for Disease Prevention and Control. Clin  
1994 Microbiol Infect. 2013;19(8):693-698. Epub 2013/04/24. doi: 10.1111/1469-0691.12230.
- 1995

- 1996 200. Lagerqvist N, Moiane B, Mapaco L, Fafetine J, Vene S, Falk KI. Antibodies against  
1997 Rift Valley fever virus in cattle, Mozambique. *Emerg Infect Dis.* 2013;19(7):1177-1179.  
1998 Epub 2013/06/15. doi: 10.3201/eid1907.130332.
- 1999
- 2000 201. Abakar MF, Nare NB, Schelling E, Hattendorf J, Alfaroukh IO, Zinsstag J.  
2001 Seroprevalence of Rift Valley fever, Q Fever, and brucellosis in ruminants on the  
2002 southeastern shore of Lake Chad. *Vector-Borne and Zoonotic Diseases.*  
2003 2014;14(10):757-762. doi: 10.1089/vbz.2014.1585.
- 2004
- 2005 202. Consultative Group for RVF Decision Support. Decision-support tool for prevention  
2006 and control of Rift Valley fever epizootics in the Greater Horn of Africa. *Am J Trop Med*  
2007 *Hyg.* 2010;83(2 Suppl):75-85. doi: 10.4269/ajtmh.2010.83s2a03.
- 2008
- 2009 203. Shah MM, Ndenga BA, Mutuku FM, Vu DM, Grossi-Soyster EN, Okuta V, et al.  
2010 High dengue burden and circulation of 4 virus serotypes among children with  
2011 undifferentiated fever, Kenya, 2014-2017. *Emerg Infect Dis.* 2020;26(11):2638-2650.  
2012 doi: 10.3201/eid2611.200960.
- 2013
- 2014 204. Vu DM, Mutai N, Heath CJ, Vulule JM, Mutuku FM, Ndenga BA, et al.  
2015 Unrecognized dengue virus infections in children, western Kenya, 2014-2015. *Emerg*  
2016 *Infect Dis.* 2017;23(11):1915-1917. doi: 10.3201/eid2311.170807.
- 2017
- 2018 205. Hortion J, Mutuku FM, Eyherabide AL, Vu DM, Boothroyd DB, Grossi-Soyster EN,  
2019 et al. Acute flavivirus and alphavirus infections among children in two different areas of  
2020 Kenya, 2015. *Am J Trop Med Hyg.* 2019;100(1):170-173. doi: 10.4269/ajtmh.18-0297.
- 2021
- 2022 206. Hertz JT, Munishi OM, Ooi EE, Howe S, Lim WY, Chow A, et al. Chikungunya and  
2023 dengue fever among hospitalized febrile patients in northern Tanzania. *Am J Trop Med*  
2024 *Hyg.* 2012;86(1):171-177. doi: 10.4269/ajtmh.2012.11-0393.
- 2025
- 2026 207. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus  
2027 (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology,  
2028 vectors, diagnostics and prevention. *Vet Res.* 2010;41(6):61. Epub 2010/12/29. doi:  
2029 10.1051/vetres/2010033.
- 2030
- 2031 208. Fakour S, Naserabadi S, Ahmadi E. The first positive serological study on Rift  
2032 Valley fever in ruminants of Iran. *J Vector Borne Dis.* 2017;54(4):348-352. Epub  
2033 2018/02/21. doi: 10.4103/0972-9062.225840.
- 2034

2035 209. Amato L, Dente MG, Calistri P, Declich S. Integrated early warning surveillance:  
2036 Achilles' Heel of One Health? *Microorganisms*. 2020;8(1). doi:  
2037 10.3390/microorganisms8010084.

2038  
2039 210. Hassan OA, Ahlm C, Evander M. A need for One Health approach - lessons  
2040 learned from outbreaks of Rift Valley fever in Saudi Arabia and Sudan. *Infect Ecol*  
2041 *Epidemiol*. 2014;4. Epub 2014/02/08. doi: 10.3402/iee.v4.20710.

2042

## 2043 **Supporting Information**

### 2044 ***Text:***

2045 **S1 Text.** Information sources and detailed scripts used in running the searches on the  
2046 online databases

### 2047 ***Figures:***

2048 **S1 Figure.** Forest Plot for meta-analysis of the impact of butchering on odds of RVFV  
2049 exposure

2050 **S2 Figure.** Forest Plot for meta-analysis of the impact of sheltering animals on odds of  
2051 RVFV exposure

2052 **S3 Figure.** Forest Plot for meta-analysis of the impact of milking animals on odds of  
2053 RVFV exposure

### 2054 ***Tables:***

2055 **S1 Table.** PRISMA checklist

2056 **S2 Table.** Listing of included studies with full citations

2057 **S3 Table.** Listing of excluded studies with full citations

2058 **S4 Table.** Listing by year of countries experiencing human or animal exposure to RVFV  
2059 during 1999-2021

2060 **S5 Table.** Listing of acute human cases reported during 1999-2021. Outbreaks are  
2061 indicated by year, country, region, and geographic location, with estimated population  
2062 size, incidence, and case fatality rates

2063 **S6 Table.** Studies of RVFV lineage distribution based on genetic sequence analysis

2064 **S7 Table.** 1999-2021 studies of local insect vector presence and RVFV infection

2065 **S8 Table.** Studies assessing human risk factors related to animal exposures and severe  
2066 RVFV disease

2067 **S9 Table.** Studies of the effects of socioeconomic status on human RVFV exposure risk

2068 **S10 Table.** Studies of the effects of occupation on human RVFV exposure risk

2069 **S11 Table.** Livestock factors related to animal RVFV exposure risk

2070 **S12 Table.** Wildlife anti-RVFV seroprevalence reported in included studies

2071 **S13 Table.** Local and national RVF surveillance systems reported in included studies

2072